



Date: 07th September, 2021

To,

BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

Scrip Code: 541299 (Dr Lalchandani Labs Limited)

Sub: Regulation 34 of the SEBI (Listing Obligation and disclosure Requirements) Regulation, 2015- Annual Report for the year ended 31st March, 2021.

Dear Sir/ Madam,

Pursuant to Regulation 34 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, we are submitting herewith Annual Report for the year ended 31st March, 2021 and the same has also been uploaded on Company's Website.


Kindly find the same in order.

Thanking you,

Yours faithfully,
For Dr Lalchandani Labs Limited



Arjan Lalchandani
Managing Director
DIN- 07014579



Dr Lalchandani Labs Limited

**Annual Report
(2020-2021)**



Dr Lalchandani 
Since 1986



Facts about us

Dr Lalchandani lab is situated at Greater Kailash, New Delhi State of the art NABL accredited lab in existence since 1986 with fully automatic machines offering world-class diagnostic lab services in New Delhi

All routine and specialized Biochemistry, Hormone assays, Drug assays, cancer markers, Torch Tests, Elisa T.B., Ultra Sound Test, Colour Doppler Test, Pap Smear and Histopathology studies are performed offering Affordable Health Packages in New Delhi like - Platinum Health Package, Gold Health Checkup, Complete Body Profile, Basic Blood Profile Tests.

Employs full time staff of pathologists, trained technicians and quality manager with experience ranging from 5-25 years and offers Hospital Lab Management in New Delhi. Dr Lalchandani Labs also offers Best Corporate Health Checkups, Blood Bank Services across Delhi NCR.

We are empaneled for all major panels such as CGHS (South, North and East Block), DJB, MCD, DDA etc. and offer all the services at home with Home Collection & Checkups.

State of the art NABL accredited lab in existence for 28 years with fully automatic machines:

- ✓ All routine and specialized Biochemistry, Hormone assays, Drug assays, cancer markers, Torch Tests, Elisa T.B., Pap smear and Histopathology studies.
- ✓ Ability to process 1000 samples/hour with same day reporting.
- ✓ Reputed suppliers such as Johnson & Johnson, Roche, Nicholas Piramal etc.
- ✓ Maintain robust documentation, control checks and Quality logs as per NABL.

Employs full time staff of pathologists, trained technicians and quality manager with experience ranging from 5-25 years.

5 Self-sufficient Labs and 15 collection centers across Delhi/NCR.

Empaneled for all major panels such as CGHS, DJB, MCD, DDA etc.

Regular participate in External Quality Assurance Service (EQAS) along with prestigious institutes like AIIMS, Vellore & Sir Ganga Ram Hospital.



CONTENTS

	<u>Page Nos.</u>
<u>Letter to Shareholders</u>	
• <i>Message From the Chairman</i>	4-5
• <i>Board of Directors</i>	6
• <i>Corporate Information</i>	7-8
<u>Notice of Annual General Meeting</u>	
• <i>Notice of AGM</i>	9-12
• <i>Route Map to the venue of AGM</i>	13
<u>Statutory Reports</u>	
• <i>Board's Report</i>	14-19
<i>Annexures to Board's Report</i>	
○ <i>Annexure I- AOC-2</i>	20
○ <i>Annexure II- MGT-9</i>	21-28
○ <i>Annexure III- Composition of the Board</i>	29
○ <i>Annexure IV- Declaration Regarding Code Of Conduct</i>	30
○ <i>Annexure V- Management Discussion and Analysis Report</i>	31-34
○ <i>Annexure VI- Secretarial Audit Report</i>	35-38
○ <i>CEO/CFO Certificate</i>	39
<u>Financials</u>	
• <i>Independent Auditor's Report</i>	40-45
• <i>Balance Sheet</i>	46
• <i>Profit & Loss Statement</i>	47
• <i>Cash Flow Statement</i>	48
• <i>Notes to Financial Statement</i>	49-58
• <i>Notes to Accounts and Significant Policies</i>	59-66
• <i>Attendance Slip</i>	67
• <i>MGT-11 Proxy Form</i>	68-70



Dr Arjan Lalchandani
Chairman & Managing Director

From the Chairman's Desk

Dear Shareholders,

It is my pleasure to welcome you all to the 04th Annual General Meeting of Dr Lalchandani Labs Limited for the year 2020-2021.

Dr Lalchandani Labs Limited is an NABL accredited lab functional in the area of pathology, radiology, hospital lab management, doctor consultation, corporate health check-ups since inception of our pathology lab as a proprietorship firm in the year 1986 and we have been trying to cater our clients with excellent pathology and diagnostic services. In order to achieve the said goal, we arrange various training programs for our staff members to equip them with the latest technologies and amendments to cope up with the changing needs of the market.

We expect Dr Lalchandani Labs Limited to be one of the top listed laboratories offering pathology and diagnostic services in next 5 years with various labs and diagnostic centers at different regions of the country.

The company has strong belief to fulfill its commitment and make all dedicated as well as sincere efforts in executing its planning and strategies. Accordingly, the company spreading its wings in almost each and every corner of India by developing requisite infrastructure in order to provide desired/satisfactory services to our valued customers.

The continued growth of the company in this situation of COVID -19 we are always been proactive in supporting various Government Initiatives and helping communities around us and had successfully obtain the approval from Indian Council of Medical Research [ICMR] for COVID -19 RT-PCR testing.

The growth of the company could not be well accelerated without the help of our lending institutes who have supported in our liquidity requirements at the continuous interval, we are generous to have their confidence in our vision and future prospects.

At the end I would also like to place on record my sincere thanks to all our well-wishers, associates, vendors, customers, employees and members of the Board who have contributed to the success of your Company. Lastly, I would also like to thank all the stakeholders for their loyalty and continuous support in helping us achieve our vision of bringing quality health care to our society and also look forward to a positive interaction with all in the days to come.

Sd/-

Dr Arjan Lalchandani
Chairman & Managing Director
Dr Lalchandani Labs Limited

Dr Lalchandani  *abs*
Since 1986

Board of Directors



Dr Arjan Lalchandani
Chairman & Managing Director



Mohit Lalchandani
Whole Time Director/ CEO




Anchal Gupta
Executive Director/CFO



Manica Gupta
Non-Executive Director



Prakash Jhuraney
Independent Director



Dr Rajiv Handa
Independent Director

CORPORATE INFORMATION

Board of Directors and Key Managerial Personnel:

Dr. Arjan Lalchandani (DIN: 07014579)	Chairman and Managing Director
Mr. Mohit Lalchandani (DIN: 07873508)	Whole-time Director/ CEO
Mrs. Anchal Gupta (DIN: 07873466)	Executive Director /CFO
Ms. Manica Gupta (DIN: 08436144)	Non-Executive Director
Mr. Rajiv Handa (DIN: 08036399)	Independent Director
Mr. Prakash Jhuraney (DIN: 08211777)	Independent Director
Miss. Swati Poddar	Company Secretary and Compliance Officer

Committee:

Audit Committee:

Mr. Prakash Jhuraney	Chairman
Mr. Rajiv Handa	Member
Mr. Mohit Lalchandani	Member

Nomination and Remuneration Committee:

Mr. Rajiv Handa	Chairman
Mr. Prakash Jhuraney	Member
Ms. Manica Gupta	Member

Stakeholders' Relationship Committee:

Mr. Rajiv Handa	Chairman
Mr. Prakash Jhuraney	Member
Ms. Manica Gupta	Member

OTHER INFORMATION

Registered Office

M-20, Basement, Greater Kailash,
Part-1, New Delhi-110048
Email: info@lalchandaniopathlab.com
Tel: 011-49057058/59; web: http://www.lalchandaniopathlab.com/

Registrar & Share Transfer Agent

M/s. Cameo Corporate Services Ltd.
Subramanian Building, 1 Club House Road,
Chennai - 600 002
Tel No.: +91-44-2846 0390/1989
Fax No.: +91-44-2846 0129
Website: www.cameoindia.com
E-mail ID: cameo@cameoindia.com

Statutory Auditors

M/s. Jain Agarwal & Company,
Chartered Accountants
BB-80 B (West), Shalimar Bagh, New Delhi-110088
Tel : 011- 47479799
Contact Person: CA Karan Jain

Listing

BSE Limited- SME Platform
PJ Towers, Dalal Street
Mumbai-400001
(w.e.f., 9th May, 2018)



Important Communication to Members

The Ministry of Corporate Affairs has taken a "Green Initiative in the Corporate Governance" by allowing paperless compliances by the companies and has issued circulars stating that service of notice/documents including Annual Report can be sent by e-mail to its members. To support this green initiative of the Government in full measure, members who have holdings with the Depository through their concerned Depository Participants. Members who hold shares in physical form not registered their e-mail addresses, so far, are requested to register their e-mail addresses, in respect of electronic are requested to update their email address with the Company or M/s. Cameo Corporate Services Ltd. (RTA), to enable us to send all the documents through electronic mode in future.

DR LALCHANDANI LABS LIMITED

(CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi-110048

Tel: 011-49057058/59

Email: info@lalchandaniopathlab.com; Website: <http://www.lalchandaniopathlab.com>

NOTICE

04TH ANNUAL GENERAL MEETING

NOTICE is hereby given that the 04th Annual General Meeting of the Members of **Dr Lalchandani Labs Limited** will be held on Wednesday, 29th September, 2021 at 3.00 p.m. at Golden Palms Hotel situated at 6 C, Opposite Police Headquarter, Patparganj, New Delhi-110092 to transact with or without modification(s), as may be permissible, the following business:

ORDINARY BUSINESS: -

1. To consider and adopt the audited standalone financial statements of the Company for the Financial Year ended March 31, 2021, together with the Reports of the Board of Directors and the Auditors thereon.
2. To approve, with or without modification, re-appoint a director Mrs. Anchal Gupta (DIN: 07873466) who retires by rotation at this annual general meeting and being eligible offers herself for re-appointment.

**For & on behalf of the Board of Directors
Dr Lalchandani Labs Limited**

Place: New Delhi
Date: 06th September, 2021

Sd/-
Arjan Lalchandani
Managing Director
(DIN: 07014579)

NOTES: -

1. In view of the COVID-19 pandemic, we have made arrangement of social distancing and members are requested to wear the mask while entering the venue for annual general meeting.
2. A member entitled to attend and vote at the annual general meeting (AGM) is entitled to appoint a proxy/ proxies to attend and vote instead of himself/ herself and the proxy/ proxies need not be a member of the company.

Instrument appointing proxy/proxies, in order to be effective, should be deposited at the registered office of the company situated at M-20, Basement, Greater Kailash-1, New Delhi-110048, not less than 48 hours before the time fixed for commencement of the annual general meeting.

3. A person can act as proxy on behalf of Members not exceeding Fifty (50) and holding in the aggregate not more than 10% of the total share capital of the Company. In case a proxy is proposed to be appointed by a Member holding more than 10% of the total share capital of the Company carrying voting rights, then such proxy shall not act as a proxy for any other person or shareholder.
4. Corporate members intending to send their authorized representatives to attend the meeting are requested to send a certified copy of the Board Resolution authorizing their representatives to attend and vote on their behalf at the meeting.
5. During the period beginning twenty-four (24) hours before the time fixed for the commencement of the meeting and ending with the conclusion of the meeting, members would be entitled to inspect the proxies lodged, at any time during the business hour of the company, provided not less than three (3) days' written notice in this respect is given to the company.
6. **Members, proxies and authorized representatives are requested to carry to the meeting, the attendance slips enclosed herewith duly completed and signed mentioning therein details of their DP id and client id/ folio no.**
7. In case of Joint-holders attending the meeting, only such joint holder who is higher in the order of names will be entitled to vote.
8. The Company has notified closure of register of members and transfer books from 21st September, 2021 to 29th September, 2021 (both days inclusive).
9. The register of Directors and Key Managerial Personnel and their shareholding maintained under section 170 of the Act and the Register of Contracts and Arrangements in which directors are interested maintained under section 189 of the Act, shall be made available at the commencement of the meeting and shall remain open and accessible to the members during the continuance of the meeting.
10. The Company has notified 20th September, 2021 as record date/ cutoff date for the purpose of determining the eligibility of the Members to attend and cast vote at Annual General Meeting.
11. Company is exempted from conducting E-Voting vide Rule 20(2) of Companies (Management & Administration) Amendment Rule, 2015. So, voting will be conducted by means of Ballot papers at the Annual General Meeting. A person, whose name is recorded in the register of the members or in the register of Beneficial owners maintained by the Depositories as on the cut-off date only shall be entitled to vote at the AGM.
12. Pursuant to Section 72 of the Companies Act, 2013, members holding shares in physical form may file nomination in the prescribed Form SH-13 and for cancellation / variation in nomination in the prescribed Form SH-14 with the Company's RTA. In respect of shares held in electronic / demat form, the nomination form may be filed with the respective Depository Participant.
13. Members are requested to bring their copy of Annual Report and the Attendance Slip which is duly completed and signed, mentioning therein details of their DP ID and Client ID / Folio No. with them at the Annual General Meeting as a measure of economy as the same will not be supplied again at the meeting.
14. All documents mentioned in the accompanying notice are open for inspection at the registered office of the Company between 10 A.M. to 4 P.M. on all working days except Saturday and Sunday up to and including the date of this Annual General Meeting.


15. To support the 'Green Initiative' in the Corporate Governance taken by the Ministry of the Corporate Affairs, to contribute towards the Greener Environment and to receive all documents, Notices, including Annual Reports and other communications of the Company, investors should register their Email Address with RTA if shares are held in physical mode or with the depository participants if the shares held in electronic mode.
16. Electronic Copy of the Notice of the 04th Annual General Meeting (AGM) along with Attendance slip, Proxy Form, and Annual report for F.Y. 2020-2021, is being sent to all the members whose email ids are registered with the Company/ Depository Participant(s)/ RTA for communication purposes, unless any member has requested for a physical copy of the same. For members who have not registered their email address, physical copy of the Annual Report for F.Y.2020-2021 and Notice of AGM are being sent in the permitted mode. Even after registering for e-communication, members are entitled to receive such communication in physical form, upon making a request for the same, free of cost. For any communication, the shareholders may also send request to the email id: cs@lalchandanipathlab.com. SHAREHOLDERS ARE REQUESTED TO PLEASE NOTE THAT ALL THE QUERIES SHOULD BE GIVEN IN WRITING TO THE COMPANY BEFORE 48 HOURS OF THE ANNUAL GENERAL MEETING.
17. Members may also note that the notice of the AGM and the Annual Report for the financial year 2020-2021 will also be available on the Company's website www.drlalchandanipathlab.com for download. The physical copy of the aforesaid documents will be available at the Company's registered office in New Delhi at M-20, Greater Kailash-1, New Delhi- 110048 for inspection during normal business hours on all working days except Saturday and Sunday, up to and including the date of AGM.
18. Members holding shares in the dematerialized mode are requested to intimate all changes with respect to their bank details, ECS mandate, nomination, power of attorney, change of address, change in name etc., to their Depository Participant (DP). These changes will be automatically reflected in the Company's records, which will help the Company to provide efficient and better service to the Members. Members holding shares in physical form are requested to intimate the changes to the Registrar & Share Transfer Agents of the Company (RTA).
19. The Shareholders holding Shares in Physical form are advised to get their shares dematerialized as no physical shares can be traded in the Stock Exchanges in terms of SEBI and Stock Exchange guidelines.
20. **This is to bring to the notice of the Shareholders that the request for effecting transfer of securities held in Physical form (except in case of transmission or transposition) would not be entertained and shall not be processed by the Company/ RTA of the Company w.e.f. 5th December, 2018 pursuant to SEBI Notification No. SEBI/LADNRO/GN/2018/24 dated 8th June, 2018. Hence Shareholders are advised to get their physical shares transferred / dematerialized.**
21. Members may please note that no gifts, gift coupons, or cash in lieu of gifts will be distributed at meeting, in compliance with Section 118(10) of the Companies Act, 2013 and the Secretarial Standards issued by Institute of Company Secretaries of India.
22. To comply with Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 it is mandatory for all the investors including transferors to complete their KYC information. The Company have to update the member's PAN No., Phone No., e-mail address and signature in the records. Kindly furnish the same via email at cs@lalchandanipathlab.com or via hand delivery or courier the same to the registered office of the Company.
23. **Voting**
 - i. The facility for voting through ballot paper shall be made available at the AGM and the members attending the meeting will be able to exercise their right at the meeting through ballot

paper. The Cut-off Date for determining the members who are entitled to vote through ballot Paper process is 20th September, 2021, only Members as on the cut-off date, would be entitled to vote at the meeting.

- ii. Mrs. Heena Taneja (Membership No. -ACS 50084 & COP No.-21920) of M/s. Heena Taneja & Associates, Practicing Company Secretaries, a sole proprietorship firm has been appointed as the Secretarial Auditor and Scrutinizer of the Company for Financial Year 2020-2021 to conduct the secretarial audit.
 - iii. The Scrutinizer shall after the conclusion of voting at the general meeting, will count the votes cast at the meeting in the presence of at least two witnesses not in the employment of the Company and shall make, within a period not exceeding 48 hours from the conclusion of meeting, a Scrutinizer's report of the total votes cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same and declare the result of the voting forthwith.
24. Route Map showing directions to reach the Venue of the 04th Annual General Meeting is annexed herewith.
25. Information of Director seeking re-appointment at the Annual General Meeting to be held on 29th September, 2021.

Name of Director	Mrs. Anchal Gupta
DIN	07873466
Designation	Executive Director
Date of Appointment	02/08/2017
Date of Birth	12/11/1986
Qualification	Master of Science of Humanities and Social Science in International Business
Expertise in specific functional area	She is having more than 4 years of experience in operations and Human Resource Management.
Relationship between Directors inter-se	Mr. Mohit Lalchandani, Whole Time Director is husband of Mrs. Anchal Gupta, Mr. Arjan Lalchandani, Managing Director and Chairman is Father-in-Law of Mrs. Anchal Gupta
Directorships held in other listed companies	NIL
Membership/ Chairmanship of Committees of other public companies -includes only audit committee and stakeholder relationship committee	NIL
Shareholding in the company	36152

With reference to SS-2, for the easy convenience of recipients of notice, Route map to the venue of Annual General Meeting of the Company is as under:



BOARD OF DIRECTOR'S REPORT

To
The Members
DR LALCHANDANI LABS LIMITED

The Directors take pleasure in presenting the 04th Annual Report together with the Audited Financial Accounts for the year ended 31st March, 2021.

1. Financial Performance: -

The financial performance of the Company for the Year ended 31st March, 2021 is as summarized below: -

Particulars	2020-2021	2019-2020
Gross Turnover & Other Income	9,77,99,874	6,10,38,720
Profit before Interest, Depreciation & Taxation	2,24,64,831	1,26,88,544
Less-Interest	35,38,154	18,49,827
Profit/(Loss) before Depreciation & Taxation	1,89,26,676	1,08,38,717
Less-Depreciation	51,52,719	38,38,964
Profit/(Loss) before tax	1,37,73,957	69,99,753
Less-Provision for Taxation (Incl. Deferred Tax)	36,60,559	22,57,318
Net Profit/ (Loss) for the year	1,01,13,398	47,42,435
Balance Carried to Balance Sheet	1,01,13,398	47,42,435

2. Performance Review: -

Your directors report that for the year under review, your Company has been able to achieve Turnover of Rs. 978.00 Lakhs. The revenue from operations for the year is Rs. 978.00 Lakhs.

3. Capital Structure: -

During the year under review, there is no change in the Authorized and Issued Share Capital of the Company.

4. Dividend: -

Your directors do not recommend any dividend for the year 2020-2021 as under review.

5. Deposit: -

During the year under review your company has not accepted any deposits from the public and therefore no information is required to be furnished in respect of outstanding deposits.

6. Change in Nature of Business: -

There is no significant change made in the nature of the company during the financial year.

7. Transfer to Reserve: -

The Company has transferred current year's profit of Rs. 101.13 Lakhs to the Reserve & Surplus and the same is in compliance with the applicable provisions prescribed under the Companies Act, 2013.

8. Details of Directors and Key Managerial Personnel: -

During the year under review, following changes in Directors and Key Managerial Personnel are mentioned below-

Mrs. Anchal Gupta, (DIN-07873466) Director, retire from board by rotation and being eligible has offered herself for re-appointment at the ensuing Annual General Meeting.

As on 31st March, 2021 shareholding of directors in the company is given below-

S.No.	Name of Director	Shares Held	Holding (in %)
1	Dr Arjan Lalchandani	2386851	55.08
2	Mr. Mohit Lalchandani	210807	4.86
3	Mrs. Anchal Gupta	36152	0.83

Brief composition of Board of Directors of the Company is annexed to this report as **Annexure - III**.

NO MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY WHICH HAVE OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR OF THE COMPANY TO WHICH THE FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT

7. Directors' Responsibility Statement: -

Your Director state that:

- a) In the preparation of the annual accounts for the financial year 2020-2021, the applicable accounting standards read with requirements set out under Schedule III of the Companies Act, 2013, have been followed and there are no material departures from the same;
- b) Appropriate accounting policies have been selected and applied consistently and such judgments & estimates have been made that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as on 31st March, 2021 and of the Profit and loss of the Company for the accounting year ended on that date;
- c) Proper & sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing & detecting fraud and other irregularities; and
- d) The annual accounts of the Company have been prepared on a going concern basis.
- e) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.
- f) The Directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.

8. Statutory Auditors: -

M/s. Jain Agarwal & Company, Chartered Accountants (Firm Registration Number- 024866N), who are the Statutory Auditor of the Company, hold office till the Conclusion of the ensuing AGM to be held for the financial year ended 2023-2024.

9. Auditors' Report: -

The Notes on Financial statement referred to in the Auditors report are self - explanatory and do not call for any further comments. The Auditor's Report does not contain any qualification, reservation or adverse remark.

10. Subsidiary Company: - Currently, your company does not have any subsidiary.

11. Secretarial Auditors Report: -

As per the provisions of Section 204 of the Companies Act, 2013, the Board of Directors of the Company have appointed M/s. Heena Teneja & Associates, Practicing Company Secretary firm (ACS 50084 & COP No.-21920) as Secretarial Auditor and Scrutinizer to conduct Secretarial audit and scrutiny of the Company for the financial year ended on March 31,2021. Secretarial Audit Report issued by M/s. Heena Teneja & Associates; Practicing Company Secretary firm inform MR-3 is enclosed as **Annexure – VI** to this Annual Report.

12. Tax Provisions: -

The Company has made adequate provisions as required under the provisions of Income Tax Act, 1961 as well as other relevant laws governing taxation on the company.

13. Corporate Governance: -

Company is listed on BSE-SME. Hence, Corporate Governance Report is not applicable to the Company for financial year 2020-2021.

14. Conservation of energy, technology absorption and foreign exchange earnings and outgo: -

The particular as prescribed under sub-Section (3) (m) of section 134 of the Companies Act, 2013 read with Rule 8(3) the Companies (Accounts) Rules, 2014,

(i) Part A and B of the Rules, pertaining to conservation of energy and technology absorption, are not applicable to the Company.

(ii) Foreign Exchange Earnings and Outgo:

Foreign Exchange Earned - NIL

Foreign Exchange Used - NIL

15. Corporate Social Responsibility: -

The Company is not required to constitute a Corporate Social Responsibility Committee as it does not fall within purview of Section 135(1) of the Companies Act, 2013 and hence it is not required to formulate policy on Corporate Social Responsibility.

16. Particulars of employees: -

The information required under Section 197 of the Act and rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are given below:

Name of the Director	Designation	Remuneration Paid in FY 2020-2021 (In Rs.)	% Increase of remuneration in 2021 as compared to 2019 previous year	Ratio /Times per Median of employee remuneration
Arjan Lalchandani	Managing Director	11,50,000	NA	NA
Mohit Lalchandani	Whole-time Director/ CEO	11,50,000	NA	NA
Anchal Gupta	Executive Director/CFO	5,75,000	NA	NA
Manica Gupta	Non-Executive Director	NIL	NA	NA
Prakash Jhuraney	Independent Director	NIL	NA	NA
Rajiv Handa	Independent Director	NIL	NA	NA

Swati Poddar	Company Secretary	2,75,000	NA	NA
--------------	-------------------	----------	----	----

There is no employee who is drawing remuneration more than One Crore and Two Lakhs per annum, more than Eight Lakhs and Fifty Thousand per month and more than the remuneration of Managing Director or Whole-time Director.

The Board confirms that the remunerations paid to the directors is as per the remuneration policy.

17. Number of Meetings of the Board of Directors: -

During the year ended March 31, 2021, six (6) Board Meetings were held.

Sr. No.	Date on which Board Meetings were held
1	28th July, 2020
2	04th September, 2020
3	07th October, 2020
4	04th November, 2020
5	13th November, 2020
6	13th March, 2021

- 18. Statement on Declaration Given by Independent Directors Under Sub-Section (6) Of Section 149: -**
The independent directors have provided their declaration, as required pursuant to Section 149(7) of the Companies Act, 2013 stating that they meet the criteria of independence as provided in sub-Section (6).

- 19. Particulars of Loan, Guarantees and Investments by Company: -**
During the financial year ended March 31, 2021, no loan, guarantee and investment under Section 186 of the Companies Act, 2013 was made by the Company.

- 20. Related Party Transactions: -**
During the year under review, besides the transactions reported in Notes to Accounts and AOC-2 (Annexure -I), forming part of the Annual Report. There were no other related party transactions with its promoters, directors, directors and management that had a potential conflict of interest of the Company at large.

- 21. Extract of Annual Return:-**
The Extract of Annual Return is prepared in Form MGT-9 as per the provisions of the Companies Act, 2013 and Rule 12 of Companies (Management and Administration) Rules, 2014 and the same is enclosed as Annexure - II to this Report.

WEB ADDRESS FOR ANNUAL RETURN:

<http://lalchandaniathlab.com>

- 22. Significant and Material Orders Passed By the Regulators or Court:-**
There are no Significant and Material orders passed by the regulators or Courts that would impact the going concern status of the Company and its future operations.

- 23. Audit Committee: -**
In accordance with the provisions of Section 177 of the Companies Act, 2013, there is no change in the constitute of an Audit Committee. Audit Committee acts in accordance with the terms of reference specified from time to time by the Board.

There is no such incidence where Board has not accepted the recommendation of the Audit Committee during the year under review.

- 24. Nomination and Remuneration Committee: -**

In accordance with the provisions of Section 178(1) of the Companies Act, 2013, there is no change in the constitute a Nomination and Remuneration Committee. Nomination and Remuneration Committee acts in accordance with the terms of reference specified from time to time by the Board.

25. Stakeholders Relationship Committee: -

In accordance with the provisions of Section 178(5) of the Companies Act, 2013, there is no change in the constitute of a Stakeholders Relationship Committee. Stakeholders Relationship Committee acts in accordance with the terms of reference specified from time to time by the Board.

26. Reporting Under the Provisions of Sexual Harassment of Women at Workplace (Prevention, Prohibition And Redressal) Act, 2013:-

The company has in place a policy for prevention of sexual harassment in accordance with the requirements of the Sexual Harassment of women at workplace (Prevention, Prohibition & Redressal) Act, 2013.

The Company has framed proper policy to redress complaints received regarding sexual harassment. All employees (permanent, contractual, temporary, trainees) are covered under this policy. As per Section 22 and 28 of the Sexual harassment of Women at Workplace (prevention, prohibition and redressal) Act, 2013, the Internal Complaints Committee (ICC) has been set up to redress complaints received regarding sexual harassment.

No Sexual harassment complaints have been received and disposed off during the financial year 2020-2021.

Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

- a. number of complaints filed during the financial year: Nil
- b. number of complaints disposed of during the financial year: N.A.
- c. number of complaints pending as on end of the financial year: Nil

27. Compliance with the Code of Conduct: -

The Board of Directors has laid down a Code of Conduct to be followed by the board members and all senior Managerial personnel of the company.

All Board Members and senior management Executives have affirmed compliance with the code of conduct for the Financial Year 2020-2021. (**Annexure - IV**)

28. Management Discussion and Analysis Report

Management Discussion and Analysis Report for the year under review, is presented in a separate section forming part of the Annual Report and is annexed herewith as **Annexure - V**.

29. Details in Respect of Adequacy of Internal Financial Controls with Reference to the Financial Statement:-

Internal Control Systems has been designed to provide reasonable assurance that assets are safeguarded, transactions are executed in accordance's with management's authorization and properly recorded and accounting records are adequate for preparation of financial statements and other financial information. Internal check is conducted on a periodical basis to ascertain the adequacy and effectiveness of internal control systems.

Further, the testing of such controls shall also be carried out independently by the Statutory Auditors as mandated under the provisions of the Companies Act, 2013.

In the opinion of the Board, the existing internal control framework is adequate and commensurate to the size and nature of the business of the Company.

30. Risk Management Policy:-

The Company has established a well-defined process of risk management, wherein the identification, analysis and assessment of the various risks, measuring of the probable impact of such risks, formulation of risk mitigation strategy and implementation of the same takes place in a structured manner. Though the various risks associated with the business cannot be eliminated completely, all efforts are made to minimize the impact of such risks on the operations of the Company. The Company on various activities also puts necessary internal control systems in place across the board to ensure that business operations are directed towards attaining the stated organizational objectives with optimum utilization of the resources.

31. Nomination and Remuneration policy of Directors, Key Managerial Personnel And other Employees:-

In adherence of Section 178(1) of the Companies Act, 2013, the Board of Directors of the Company in its Meetings, approved a policy on directors' appointment and remuneration including criteria for determining qualifications, positive attributes, independence of a director and other matters provided u/s 178(3), based on the recommendations of the Nomination and Remuneration Committee. The broad parameters covered under the Policy are - Company Philosophy, Guiding Principles, Nomination of Directors, Remuneration of Directors, Nomination and Remuneration of the Key Managerial Personnel (other than Managing/ Whole-time Directors), Key-Executives and Senior Management and the Remuneration of Other Employees.

32. Acknowledgement:-

The Board wishes to place on record its sincere appreciation for the assistance and co-operation received from Bankers, Government Departments and other Business Associates for their continued support towards the conduct of operations of the Company efficiently.

The Directors express their gratitude to the shareholders for their continuing confidence in the Company. The Directors also acknowledge the hard work and persuasive efforts put in by the employees of the Company in carrying forward Company's vision and mission.

**On behalf of the Board of Directors,
For Dr Lalchandani Labs Limited**

**Sd/-
Dr Arjan Lalchandani
Chairman and Managing Director
DIN-07014579**

**Place: New Delhi
Date: 06th September, 2021**

ANNEXURE - I

Form No. - AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto:

1. Details of contracts or arrangements or transactions not at arm's length basis:

- (a) Name(s) of the related party and nature of relationship: **NIL**
- (b) Nature of contracts/arrangements/transactions: **NIL**
- (c) Duration of the contracts / arrangements/transactions: **NIL**
- (d) Salient terms of the contracts or arrangements or transactions including the value, if any: **NIL**
- (e) Justification for entering into such contracts or arrangements or transactions: **NIL**
- (f) Date of approval by the Board: **NIL**
- (g) Amount paid as advances, if any: **NIL**
- (h) Date on which the special resolution was passed in general meeting as required under first proviso to Section - 188: **NIL**

2. Details of material contracts or arrangement or transactions at arm's length basis:

- (a) Name(s) of the related party and nature of relationship:

Entities in which key managerial personnel can exercise significant influence

- 1. CPC Blood Bank

Directors or Key Managerial Personnel:

- 1. Mr. Arjan Lalchandani- Managing Director of the Company
- 2. Mr. Mohit Lalchandani- Whole Time Director of the Company
- 3. Mrs. Anchal Gupta- Executive Director of the Company

Relatives of Key Managerial Personnel- Nil

- (b) Nature of contracts/arrangements/transactions:

1. **Director's remuneration**- 28,75,000/-

- 1. Mr. Arjan Lalchandani – 11,50,000/-
- 2. Mr. Mohit Lalchandani – 11,50,000/-
- 3. Mrs. Anchal Gupta – 5,75,000/-

2. **Expense Reimbursement** – 5,90,000/-

- 3. **Loan from Arjan Lalchandani**- NIL
- 4. **Loan from Mohit Lalchandani**- NIL
- 5. **Loan from Anchal Gupta**- NIL

- (c) Duration of the contracts / arrangements/transactions: **NIL**

- (d) Salient terms of the contracts or arrangements or transactions including the value, if any: **NIL**

- (e) Date(s) of approval by the Board, if any: **NIL**

ANNEXURE - II

FORM NO. MGT-9

EXTRACT OF ANNUAL RETURN
As on the financial year ended on 31st March, 2021
[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies
(Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

i.	CIN	L85320DL2017PLC321605
ii.	Registration Date	02/08/2017
iii.	Name of the Company	DR LALCHANDANI LABS LIMITED
iv.	Category/Sub-Category of the Company	Public Company-Limited by Shares
v.	Address of the Registered office and Contact Details	M-20 BASEMENT, GREATER KAILASH-1, NEW DELHI, NEW DELHI-110048 Landline- 011-49057058/59 Email-info@lalchandaniipathlab.com
vi.	Whether listed company	Yes
vii.	Name, Address and Contact details of Registrar and Transfer Agent, if any	M/s. Cameo Corporate Services Ltd. Submaramanian Building, 1ClubHouseRoad, Chennai-600002. Tel No.: +91-44-28460390/1989

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10% or more of the total turnover of the company shall be stated:-

Sr. No	Name and Description of main products/ services	NIC Code of the Product/ Service	% of total turnover of the Company
1.	Activities of Independent diagnostic/pathology laboratories	86905	100

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES-NA

Sr.No	Name and Address of The Company	CIN/ GIN	Holding/ Subsidiary/ Associate	% of Shares Held	Applicable Section

IV. SHAREHOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i) Category-wise Share Holding

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Shareholding of Promoters and Promoter Group									
(1) Indian									
a) Individual/HUF	2633810	0	2633810	60.7839	2633810	0	2633810	60.7839	0

b) Central Govt	0	0	0	0	0	0	0	0	0
c) State Govt(s)	0	0	0	0	0	0	0	0	0
d) Bodies Corp.	0	0	0	0	0	0	0	0	0
e) Banks /FI	0	0	0	0	0	0	0	0	0
f) Any Other....	0	0	0	0	0	0	0	0	0
Sub-total (A) (1) :-	2633810	0	2633810	60.7839	2633810	0	2633810	60.7839	0
(2) Foreign									
a) Individuals (NRI/ Foreign Investor)	0	0	0	0	0	0	0	0	0
b) Institutions	0	0	0	0	0	0	0	0	0
c) Bodies Corporate	0	0	0	0	0	0	0	0	0
d) Qualified Foreign Investor	0	0	0	0	0	0	0	0	0
e) Any Other	0	0	0	0	0	0	0	0	0
Sub-total (A) (2):-	0	0	0	0	0	0	0	0	0
Total shareholding of Promoter (A) = (A)(1) +(A)(2)	2633810	0	2633810	60.7839	2633810	0	2633810	60.7839	0
B. Public Shareholding									
1. Institutions									
I. FPI (Individual) Category II-									
a) Mutual Funds/UTI	0	0	0	0	0	0	0	0	0
b) Banks / Financial Institutions	0	0	0	0	0	0	0	0	0
c) Central Government	0	0	0	0	0	0	0	0	0
d) State Government	0	0	0	0	0	0	0	0	0
e) Foreign Venture Capital Funds	0	0	0	0	0	0	0	0	0
f) Insurance Companies	0	0	0	0	0	0	0	0	0
g) Foreign Institutional Investor	0	0	0	0	0	0	0	0	0
h) Qualified Foreign Investor	0	0	0	0	0	0	0	0	0

i) Others(specify)	0	0	0	0	0	0	0	0	0
Sub-total (B)(1):-	0	0	0	0	0	0	0	0	0
2. Non-Institutions									
a) Bodies Corp.									
i) Indian	80000	0	80000	1.8462	112000	0	112000	2.5847	0.7385
ii) Overseas	0	0	0	0	0	0	0	0	0
b) Individuals									
i) Individual shareholders holding nominal share capital upto Rs. 1lakh	464754	4	464754	10.7258	428758	0	428758	9.8950	-0.8308
ii) Individual shareholders holding nominal share capital in excess of Rs 1lakh	982500	0	982500	22.6744	926500	0	926500	21.3820	-1.2923
C) Qualified Foreign Investor	0	0	0	0	0	0	0	0	0
c) Others (specify)									
(i) Hindu Undivided Families	148000	0	148000	3.4155	136000	0	136000	3.1386	-0.2769
(ii) Non-Resident Indians	24000	0	24000	0.5538	40000	0	40000	0.9231	0.3692
(iii) Clearing Members	0	0	0	0	56000	0	56000	1.2923	1.2923
Sub-total (B)(2):-	172000	0	172000	3.9694	232000	0	232000	5.3541	1.3847
Total Public Shareholding (B)=(B)(1)+ (B)(2)	1699254	4	1699258	39.2160	1699254	4	1699258	39.2160	0.0000
TOTAL (A)+(B)	4333064	4	4333068	100.00	4333064	4	4333068	100.00	0.000
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	4333064	4	4333068	100.00	4333064	4	4333068	100	0

(ii) Shareholding of Promoters and Promoters group

S.No	Shareholder's Name	Shareholding at the beginning of the Year			Shareholding at the end of the year			% change in Shareholdin During the Yea
		No. of Shares	% of Total Shares of The company	% of Shares Pledged/ Encumbered To total shares	No. of shares	% of total Shares of the company	% of Shares Pledged/ encumbered To total shares	
1	Dr. Arjan Lalchandani	2386851	55.0845	0	2386851	55.0845	0	0
2	Mr. Mohit Lalchandani	210807	4.8650	0	210807	4.8650	0	0
3	Mrs. Anchal Gupta	36152	0.8343	0	36152	0.8343	0	0

(iii) Change in Promoters' Shareholding (NO CHANGES)

Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
	No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
At the beginning of the year	-	-	-	-
Sale	-	-	-	-
Purchase	-	-	-	-
At the End of the year	-	-	-	-

(iv) Shareholding Pattern of top ten Shareholders (other than Directors and Promoters):

Sr.No.		Shareholding at the beginning of the year 01/04/2020		Cumulative Shareholding during the year 31/03/2021	
		No. of Shares	% of Total Shares of the Company	No. of Shares	% of Total Shares of the Company
1	AMIT CHARAN JT1: ASHOK CHARAN				
	At the beginning of the year 01-April-2020	220000	5.0772	220000	5.0772
	At the end of the year 31-March-2021	220000	5.0772	220000	5.0772
2	LAXMIPAT DUDHERIA				
	At the beginning of the year 01-April-2020	216000	4.9849	216000	4.9849
	At the end of the Year 31-Mach-2021	216000	4.9849	216000	4.9849
3	HARSH KAPOOR				
	At the beginning of the year 01-April-2020	150000	3.4617	150000	3.4617
	At the end of the Year 31-Mar-2020	150000	3.4617	150000	3.4617
4	SINGHI DINESH KUMAR HUF				
	At the beginning of the year 01-April-2020	84000	1.9385	84000	1.9385
	Purchase 28-Aug-2020	4000	0.0923	88000	2.0308
	Sale 09-Oct-2020	(4000)	0.0923	84000	1.9385
	Purchase 23-Oct-2020	4000	0.0923	88000	2.0308

	At the end of the Year 31-March-2021	88000	2.0308	88000	2.0308
4	SINGHI DINESH KUMAR HUF				
	At the beginning of the year 01-April-2020	16000	0.3692	16000	0.3692
	At the end of the Year 31-March-2021	16000	0.3692	16000	0.3692
5	RITUPARNA PAUL				
	At the beginning of the year 01-April-2020	84000	1.9385	84000	1.9385
	Sale 13-Nov-2020	(4000)	0.0923	80000	1.8462
	Sale 20-Nov-2020	(4000)	0.0923	76000	1.7539
	Sale 04-Dec-2020	(12000)	0.2769	64000	1.4770
	Sale 08-Jan-2021	(24000)	0.5538	40000	0.9231
	Sale 31-March-2021	(12000)	0.2769	28000	0.6461
	At the end of the Year 31-March-2021	28000	0.6461	28000	0.6461
6	PAUL ASSET				
	At the beginning of the year 01-April-2020	48000	1.1077	48000	1.1077
	Sale 18-Dec-2020	(8000)	0.1846	40000	0.9231
	At the end of the Year 31-March-2021	40000	0.9231	40000	0.9231
7	RAJ KUMAR SEHGAL				
	At the beginning of the year 01-April-2020	36000	0.8308	36000	0.8308
	Purchase 26-Jun-2020	4000	0.0923	40000	0.9231
	Sale 09-Oct-2020	(24000)	0.5538	16000	0.3692
	Sale 16-Oct-2020	(12000)	0.2769	4000	0.0923
	Sale 13-Nov-2020	(4000)	0.0923	0	0.0000
	Purchase 18-Dec-2020	4000	0.0923	4000	0.0923
	Sale 25-Dec-2020	(4000)	0.0923	0	0.0000
	Purchase 05-Feb-2021	8000	0.1846	8000	0.1846
	Purchase 26-Feb-2021	20000	0.4615	28000	0.6461
	Purchase 26-Mar-2021	4000	0.0923	32000	0.7385
	Sale 31-Mar-2021	(12000)	0.2769	20000	0.4615
	At the end of the Year 31-March-2021	20000	0.4615	20000	0.4615
8	RAHUL DUA				
	At the beginning of the year 01-April-2020	32000	0.7385	32000	0.7385
	At the end of the Year 31-March-2021	32000	0.7385	32000	0.7385
9	RAMESH KUMAR THAPAR				
	At the beginning of the year 01-April-2020	30000	0.6923	30000	0.6923
	Sale 20-Nov-2020	(4000)	0.0923	26000	0.6000
	Sale 22-Jan-2021	(4000)	0.0923	22000	0.5077
	At the end of the Year 31-March-2021	22000	0.5077	22000	0.5077
10	AVANTIKA SINGH				
	At the beginning of the year 01-April-2020	28000	0.6461	28000	0.6461
	Sale 09-Oct-2020	(4000)	0.0923	24000	0.5538
	Sale 20-Nov-2020	(4000)	0.0923	20000	0.4615
	Sale 05-Mar-2021	(4000)	0.0923	16000	0.3692
	At the end of the Year 31-March-2021	16000	0.3692	16000	0.3692
11	SACHIN GUPTA				
	At the beginning of the year 01-April-2020	0	0.0000	0	0.0000

	Purchase 23-Oct-2020	4000	0.0923	4000	0.0923
	Purchase 15-Jan-2021	16000	0.3692	20000	0.4615
	Purchase 12-Feb-2021	4000	0.0923	24000	0.5538
	Purchase 26-Feb-2021	8000	0.1846	32000	0.7385
	Purchase 05-Mar-2021	12000	0.2769	44000	1.0154
	Purchase 19-Mar-2021	4000	0.0923	48000	1.1077
	At the end of the Year 31-March-2021	48000	1.1077	48000	1.1077
12	MITHUN SECURITIES PRIVATE LIMITED				
	At the beginning of the year 01-April-2020	0	0.0000	0	0.0000
	Purchase 31-Dec-2020	16000	0.3692	16000	0.3692
	Purchase 15-Jan-2021	20000	0.4615	36000	0.8308
	Purchase 12-Feb-2021	4000	0.0923	40000	0.9231
	At the end of the Year 31-March-2021	40000	0.9231	40000	0.9231
13	AJAY KUMAR SEHGAL				
	At the beginning of the year 01-April-2020	25000	0.5769	25000	0.5769
	At the end of the Year 31-March-2021	25000	0.5769	25000	0.5769

(v) Shareholding of Directors and Key Managerial Personnel:

Sr. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total Shares of the company	No. of shares	% of total Shares of The Company
	For Each of the Directors and KMP				
1.	ARJAN LAL CHANDANI				
	At the beginning of the year	2386851	55.0845	2386851	55.0845
	At the end of the Year 31-Mar-2020	2386851	55.0845	2386851	55.0845
2.	MOHIT LAL CHANDANI				
	At the beginning of the year 30-Mar-2019	210807	4.8650	210807	4.8650
	At the end of the Year 31-Mar-2020	210807	4.8650	210807	4.8650
3.	ANCHAL GUPTA				
	At the beginning of the year 30-Mar-2019	36152	0.8343	36152	0.8343
	At the end of the Year 31-Mar-2020	36152	0.8343	36152	0.8343

V. INDEBTEDNESS

Indebtedness of the Company including interest outstanding/ accrued but not due for payment

	Secured Loans	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	96,59,476.00	74,25,978.83	NA	1,70,85,454.83
ii) Interest due but not paid	-	5,896.00		5,896.00
iii) Interest accrued but not due	1,05,123.00	10,685.28		1,15,808.28
Total (i+ii+iii)	97,64,599.00	74,42,560.11	NA	1,72,07,159.11
Change in Indebtedness during The financial year				
• Addition	1,93,56,145.00	2,50,02,791.53		4,43,58,936.53
• Reduction	1,27,97,605.25	1,58,17,394.33	N.A	2,86,14,999.58
Net Change	65,58,539.75	91,85,397.20	N.A	1,57,43,936.95
Indebtedness at the End of the financial year				
i) Principal Amount	1,62,18,015.75	1,66,11,376.03	NA	3,28,29,391.78
ii) Interest due but not paid	-	-		-
iii) Interest accrued but not due	-	-		-
Total(i+ii+iii)	1,62,18,015.75	1,66,11,376.03	NA	3,28,29,391.78

XI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Directors:

Sr. No.	Particulars of Remuneration	Name of MD/WTD/Executive Director			Total Amount
		Dr Arjan Lalchandani (Managing Director)	Mohit Lalchandani (Whole Time Director/ CEO)	Anchal Gupta (Non-Executive Director)	
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	11,50,000	11,50,000	5,75,000	28,75,000
2.	Stock Option	-	-	-	-
3.	Sweat Equity	-	-	-	-
4.	Commission -as % of profit -others, specify...	-	-	-	-
5.	Others, please specify	-	-	-	-
	Total(A)	11,50,000	11,50,000	5,75,000	28,75,000
	Ceiling as per the Act	10% of Net Profit for all Executive Directors- Managing and Whole Time Director; 5% of Net profit to any one Managing or Whole Time Director			

B. Remuneration to other directors:

Sr. no.	Particulars of Remuneration	Name of Directors		Total Amount
		Mr. Rajiv Handa	Mr. Prakash Jhuraney	
1	Independent Directors	Mr. Rajiv Handa	Mr. Prakash Jhuraney	
	• Fee for attending board/ Committee meetings	Nil	Nil	Nil
	• Commission	Nil	Nil	Nil
	• Others, please specify			
	Total(1)	Nil	Nil	Nil
2	Other Non-Executive and Non-Independent Directors	Ms. Manica Gupta		
	Gross salary			
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	Nil		Nil
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	-		
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	-		
	Total(2)	Nil		Nil
	Total(B)=(1+2)	Nil		Nil
	Total Managerial Remuneration	Nil		Nil
	Overall Ceiling as per the Act	1% of Net Profit of the Company for all Non- Executive Directors		

B. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD

Sl. no.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total
1.	Gross salary				
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	Nil	2,75,000	Nil	2,75,000
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961				
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961				
2.	Stock Option	-	-	-	-
3.	Sweat Equity	-	-	-	-
4.	Commission	-	-	-	-
	- as % of profit				
	- others, specify...				
5.	Others, please specify	-	-	-	-
	Total	Nil	2,75,000	Nil	2,75,000

XII. PENALTIES/ PUNISHMENT/COMPOUNDING OFFENCES:

Against the Company, Directors and other Officer in Default under the Companies Act, 2013: NONE

ANNEXURE - III

COMPOSITION OF THE BOARD OF DIRECTORS

The composition of the Board of as on 31st March 2021 was as follows:

Category	No. of Directors
Executive Directors	3
Non-Executive Women Director	1
*Independent Non-Executive Directors	2
Total	6

By the order of Board of
For Dr Lalchandani Labs Limited

Date: 06th September, 2021
Place: New Delhi

Sd/-
Dr Arjan Lalchandani
Managing Director
DIN: 07014579

ANNEXURE - IV

DECLARATION REGARDING CODE OF CONDUCT

All Board Members and Senior Management Personnel have, for the year ended March 31, 2021 have affirmed compliance with the Code of Conduct laid down by the Board of Directors in terms of Regulation 17(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

FOR AND ON BEHALF OF BOARD OF DIRECTORS

Place:-New Delhi
Date: 06th September, 2021

Sd/-
Dr. Arjan Lalchandani
(Managing Director)
(DIN: 07014579)

Dr Lalchandani 
Since 1986

ANNEXURE - V

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

INDUSTRY STRUCTURE AND DEVELOPMENT

India has been one of the fastest growing diagnostic and pathology laboratories markets over the past few years. Several factors that are acting as drivers for the market are rise in spending's for health care, increasing awareness of health related concerns, high prevalence of diseases and penetration of health care insurance.

On the basis of the tests performed by various laboratories, the overall India diagnostic and pathology laboratory market has been segmented into radiology and pathology tests by test type. These test types are further segmented on the basis of type of test and source for tests. By source of test, pathology tests have been segmented into blood, urine, stool, and body tissue.

Also, in the developed markets, the diagnostics business is of a B2B kind. The touch point for patients is primarily the hospitals, which in turn outsource their test processing requirements to the laboratories. In India, the diagnostics business is of a B2C kind, as patients here directly approach the pathology labs to get themselves tested. At times, tests are also conducted without a doctor's prescription.

BUSINESS OVERVIEW

Our Company was originally incorporated as partnership firm at New Delhi vide Partnership Agreement dated 15th Day of September, 2011 in the name of Dr. A Lalchandani Pathology Laboratories. Thereafter, the Partnership Firm was taken over by Dr Lalchandani Labs Limited incorporated under the provisions of Companies Act, 2013 vide certificate of Incorporation dated 2nd August, 2017 issued by the Registrar of Companies, Delhi vide agreement dated 31st August, 2017. The Corporate Identification Number of our Company is L85320DL2017PLC321605.

Our Company is formed to set up, engage, collaborate, acquire, purchase, maintain, open collection centers, conduct, manage, administer, own, run laboratories for the purposes of carrying out pathological investigations of various branches of Bio-Chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Virology, Cytology, other pathological Investigations and Immunoassay, Immuno-Histochemistry, Molecular Pathology, DNA & Genetic Testing etc.

We are a provider of diagnostic and related healthcare tests and services in Delhi/NCR. Through our integrated network, we offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Our customers include individual patients, hospitals and other healthcare providers and corporate customers.

Diagnostic healthcare testing is an essential element in the delivery of healthcare services, as it provides healthcare service providers with useful information for the diagnosis and treatment of diseases.

We focus on providing patients quality diagnostic and related healthcare tests and services. We believe our focus on the patient as a customer is a critical differentiator in the diagnostic

and healthcare industries and, together with what we believe is our brand's recognition for quality diagnostic services, results in individuals and healthcare providers choosing us as their diagnostic healthcare service provider.

Our Company, a NABL Accredited Lab has established itself within Delhi/NCR various self-sufficient Labs and multiple collection centers.

Our Company has its own Blood Banking services through its sister concern CPC blood bank founded by Dr A Lalchandani himself in 1987.

Our setup at Greater Kailash-Part 1 is having technology in Diagnostics and boasts of being aesthetically one of the most beautiful diagnostic centers in India offering one-stop complete services such as pathology, X-ray, TMT, Ultrasound, 2D-echo, Doctor Consultations, Medical Fitness Examinations etc.

We have recently set up a new lab and a diagnostic centre at Punjabi Bagh New Delhi to cater customers from the West Delhi region.

SEGMENT WISE AND PRODUCT WISE PERFORMANCE

SEGMENT WISE DETAILS

Segment	Sales (in figures) ₹.	Sales (in %)
B2B Sales	6,15,58,649.61	62.94
B2C Sales	3,62,41,223.92	37.06
Total	9,77,99,873.53	100

PRODUCT WISE DETAILS

Since our company deals with provision of services of a pathology lab and a diagnostic centre, this section is not applicable to our company.

OPPORTUNITIES AND THREATS

OPPORTUNITIES

There are many aspects in the diagnostics industry in our country which provide huge growth opportunity. These are-

- Corporate Health Check ups
- Consistently increasing sample load at main lab strengthens negotiation with suppliers to give better prices for reagents improving costings and better profit margins
- Increasing B2C presence
- Lack of customer centricity in many labs
- Lack of awareness of quality parameters in consumers is an opportunity for Good Labs like us to take charge in awareness campaigns for building good reputation with consumers.

THREATS

- Few VC funded Online Startups eroding prices in market with negative cash flows and discount funded strategies.
- B2B clients such as Hospital Lab management businesses not reliable as key

position changes in hospital may influence change of lab vendors OR the hospital may choose to bring departments in-house.

- Low Barriers to entry
- Lack of regulation and licensing of Labs and lack mandatory quality norms hampers opportunities for quality labs.
- Highly competitive market with presence of both local and national players everywhere
- Highly price sensitive market.
- Lack of awareness of quality parameters to differentiate between labs

STRENGTHS

- Company Experience of 32 years with highly experienced staff retained
- Good Personal Brand Name of Dr A Lalchandani in Delhi/NCR
- Strong ties with many hospitals, doctors and nursing homes
- Customization of services for greater customer satisfaction
- Home Collection of Samples across Delhi/NCR
- Good customer follow up in dormant Stages - reminders for periodic health check-ups
- Good Online & Social Media presence in South Delhi currently
- Good Word of mouth from Doctors network about Dr Lalchandani labs Limited
- Nimble organization & management eager to adopt and change to respond to changing needs of market and customers.
- Personal Touch and active involvement of Founder and chief pathologist Dr Arjan Lalchandani
- Management is young and enterprising and open to explore all business opportunities with open mind.
- Highly Customer centric and constantly thinking of improving user experience.

HUMAN RESOURCES

Dr Lalchandani Labs Limited is a player in the diagnostics sector. The diagnostics business is a healthcare service delivery business, and thus the role of human resources is pivotal in providing excellent quality service to the customers.

The Company business has been constantly growing since the start of its business in the year 2017. Accordingly, the human resources has to be commensurate with the size and growth of the business. As per company HR policy, it has been employing suitable no. of employees from time to time of requisite qualifications and experience and requisite expertise in respective fields. The focus around the enhancing the productivity of employees. The growth in business was achieved with marginal increase in workforce strength. This was achieved by active redeployment of resources, introducing multi-taskers and job enlargements.

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

The Company has an adequate internal control system in place with systems for segregation of duties, access controls and other relevant control practices.

Our board of Directors ensure efficient conduct of business and adhere to the policies of the company thereby ensuring maintenance of timely and reliable accounting records and disclosures.

FORWARD LOOKING STATEMENT

Except for the historical information contained herein, statement in this discussion which contains words or phrases such as 'will', 'would', 'indicating', 'expected to' etc., and similar expressions or variations of such expressions may constitute 'forward-looking statements'. These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by forward-looking statements.

These risks and uncertainty includes, but are not limited to, our ability to successfully implement our strategy, future business plans, our growth and expansion in business, the impact technological implementation as well as other general risks applicable to the business or industry. The company under takes no obligation to update forward looking statements to reflect events or circumstances after the date thereof. These discussion and analysis should be read in conjunction with the company's financial statements included herein and notes thereto.

RECOVERING FROM COVID -19 PANDEMIC

While we have emerged stronger and bolder from the COVID-19 pandemic, we are acutely aware that the pandemic has widened socioeconomic inequities. Our responsibility towards our communities has increased manifold.

To deal with the unprecedented second wave, we have ramped up our response on multiple fronts - our approach has been to address short-term emergency response as well as contribute towards strengthening our public health infrastructure. Our overall healthcare efforts have built capacity and run programs, closely collaborating with the public health system, to serve geographies that have a population of over 150 million people.

Company is embarking on programs of transformation that would improve operational efficiency and embracing agility at scale. Today, the pandemic has served to accelerate this need to transform. Customers have accelerated their adoption of technology. They want partners who can help them transform themselves rapidly, at speed. They need partners who can be trusted. Who share the same business ethics and values. Also, increasingly they want partners who can challenge status quo, provide insights based on domain expertise and can provide solutions for business outcomes.

ANNEXURE - VI

FORM NO. MR-3

**SECRETARIAL AUDIT REPORT
FOR THE FINANCIAL YEAR ENDED MARCH 31, 2021**

Pursuant to Section 204 read with Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

To
The Members
Dr. Lalchandani Labs Limited
M-20 Basement, Greater Kailash-1
New Delhi-110048

We have conducted the secretarial audit of the compliance of the applicable statutory provisions and the adherence to good corporate practice by Dr Lalchandani Labs Limited (CIN: L85320DL2017PLC321605) (hereinafter called the "**Company**"). Secretarial Audit was conducted in a manner that provided us a reasonable basis for conducting corporate conducts/ statutory compliance and expressing my opinion thereon.

Based on our verification of the Company books, papers, minutes books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representative during the conduct of secretarial audit, I hereby report that in my view, the Company has, during the audit period covering the financial year ended on March 31, 2021 complied with the statutory provisions listed hereunder and also the Company has proper Board processes and compliance mechanism in place to the extent in the manner and subject to the reporting hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2021, in terms of the following acts, which may be applicable on the Company:

1. The Companies Act, 2013 and the rules framed thereunder ("**Act**");
2. The Securities Contract (Regulation) Act, 1956 and the rules framed thereunder;
3. The Depositories Act, 1996 and the regulations and byelaws framed thereunder.
4. Securities and Exchange Board of India Act, 1992 and the regulations framed thereunder;
5. Environment Protection Act, 1986 and other related laws;
6. Drugs and Cosmetics Act, 1940;
7. The Employees Provident Fund & Miscellaneous Provisions Act, 1952;
8. The Employees State Insurance Act, 1948;
9. The Employer's Liability Act, 1938;
10. Indian Contract Act, 1872;
11. Industrial Dispute Act, 1947;
12. Minimum Wages Act, 1948;
13. Payment of Bonus Act, 1965;
14. Payment of Gratuity Act, 1972;
15. Payment of Wages Act, 1936;
16. Dangerous Drugs Act, 1940;
17. The Poisonous Act 1919;
18. The Drugs and Magical Remedies (Objectionable Advertisements) Act, 1954;
19. The Prevention of Food Adulteration Act, 1954;
20. The Essential Commodities Act, 1955;
21. The Income Tax Act, 1963, Goods and Services Act, 2017 and/ or other applicable tax laws; and
22. The Boilers Act, 1923 and other related laws.

We have also examined compliance with the Secretarial Standards issued by the Institute of Company Secretaries of India.

During the period under review it seems that the Company has complied with the provisions of the laws mentioned above, to the extent applicable on the Company. Following key observations may be noted by the Company:

1. Form CHG-4 pertaining to satisfaction of charge was filed along with the additional fee.

We further report that:

The Board of Directors of the Company is duly constituted with the proper balance of Executive Directors, Non- Executive Directors and Independent Directors. There has not been any change in the composition of the board of directors of the Company during the financial year under review.

Adequate notice is given to all the directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least 7 (seven) days in advance and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decisions is carried through while the dissenting member views, if any, are captured and recorded as part of the minutes.

We further report that there are adequate system and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules and regulations.

for **Heena Taneja and Associates**
Company Secretaries

Sd/-

Place: New Delhi
Date: September 06, 2021

Heena Taneja
Proprietor
ACS No: 50084
C.P. No: - 21920

This report is to be read with our letter of even date which is annexed as 'Annexure A' and forms an integral part of this report.

‘Annexure A’

To
The Members
Dr. Lalchandani Labs Limited
M-20 Basement, Greater Kailash-1
New Delhi-110048

Our report of even date is to read along with this letter:

1. This secretarial audit report has been prepared on the basis of review of documents provided by Company representatives, our discussions with the company representatives and the laws applicable on the Company during the year under review;
2. This secretarial audit report aims only at highlighting those secretarial issues in respect of the Company which may have a significant and material impact on arrangements or matters pertaining to the Company;
3. We have not carried out independent verification of the information or documents supplied by the Company representatives from any government agency or third party;
4. This secretarial audit report is prepared on the basis of the assumptions that:
 - (i) All opinions and views expressed by the Company representatives or the agents or managers, employees and advisors of the Company in relation to the Company are honestly held by them and that all such opinions and views expressed to us were when made and continued to be based on reasonable assumptions and that all statements of fact by any of the forgoing persons were when made and continued to be true accurate, correct and not misleading in anyway;
 - (ii) All copies of documents furnished to us and examined by us are true and are complete copies of the originals of such documents and that there are no other relevant document or information;
 - (iii) All documents reviewed by us were validly executed and that the relevant parties to them had all necessary capacities under its or their constitutions to do such things;
 - (iv) No term of any document or document referred to in it has been amended by any of the parties orally or by conduct or in the course of dealing or otherwise without us being made aware of it; and
 - (v) All information and documentation supplied to, or examined by us in connection with or preparation of secretarial audit report, or from which this secretarial audit report was compiled, was and remains true and complete and is not misleading in any way.
5. In preparing the secretarial audit report we have limited our enquiries to matters of a secretarial nature and accordingly, we have neither raised queries in respect of, or otherwise investigated and, accordingly, express no opinion on any financial (including the accounts of the Company) or tax or actuarial or technical or any legal issues relating to or otherwise affecting or capable of effecting directly or indirectly the Company.
6. Maintenance of secretarial record is the responsibility of the management of the Company, our responsibility is to express an opinion on these secretarial records based on our audit;
7. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that practices and processes, we followed provide a reasonable basis on our opinion;

8. We have not verified the correctness and appropriateness of financial records and books and accounts of the Company;
9. The compliance of the provisions of Corporate and other applicable laws, rules, regulation and standards is the responsibility of the management. Our examination was limited to the verification of procedures on test basis; and
10. The Secretarial Audit is neither an assurance as to the future viability of the Company nor the efficacy or effectiveness with which the management has conducted the affairs of the Company.

for **Heena Taneja and Associates**
Company Secretaries

Sd/-

Place: New Delhi
Date: September 06, 2021

Heena Taneja
Proprietor
ACS No: 50084
C.P. No: - 21920

CEO/CFO CERTIFICATION

To,

The Board of Directors
Dr Lalchandani Labs Limited

I, Anchal Gupta, the Chief Financial Officer (CFO) of the Company do here by certify to the Board that:

1. We have reviewed financial statements and the cash flow statement for the year ending 31st March, 2021 and that to the best of their knowledge and belief:

(i) These statements do not contain any materially untrue statement or omit any material factor contain statements that might be misleading;

(ii) These statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.

2. There are, to the best of our knowledge and belief, no transactions entered into by the company during the year which are fraudulent, illegal or violate of the company's code of conduct.

3. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the company pertaining to financial reporting and we have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.

4. We have indicated to the auditors and the Audit committee:

(i) Significant changes in internal control over financial reporting during the year;

(ii) Significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and

(iii) Instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the company's internal control system over financial reporting;

For Dr Lalchandani Labs Limited

Date: 06th September, 2021
Place: New Delhi

Sd/-
Anchal Gupta
Director/ Chief Financial Officer
(DIN: 07873466)

Standalone Financial Statements

Independent Auditor's Report

To the members of Dr Lalchandani Labs Limited

Report on the standalone financial statements

We have audited the financial statements of Dr Lalchandani Labs Limited comprising of the Balance Sheet as at March 31, 2021, the Statement of Profit and Loss and Cash Flow Statement for the year ended, and a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the financial statements").

Management's Responsibility for the financial statements

The Company's Board of Directors is responsible for the preparation of these financial statements in terms of the requirement of the Companies Act, 2013 ("the Act") that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 and Companies (Accounting Standards) Amendment Rules, 2016. The respective Board of Directors of the companies are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the financial statements by the Directors of the Company, as aforesaid.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. While conducting the audit, we have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder. We conducted our audit in accordance with the Standards on Auditing, issued by the Institute of Chartered Accountants of India, as specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's Board of Directors, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, as at March 31, 2021, their profit, and their cash flows for the year ended on that date.

Report on other legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2015 ("the Order") issued by the Central Government of India in terms of subsection (11) of section 143 of the Act, we enclose in the "Annexure 1", a statement on the matters specified in Paragraph's 3 and 4 of the Order.
2. As required by Section 143(3) of the Act, based on our audit, we report, to the extent applicable, that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the aforesaid financial statements;
 - (b) In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - (c) The Balance Sheet, Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account maintained for the purpose of preparation of the financial statements;

- (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 and Companies (Accounting Standards) Amendment Rules, 2016;
- (e) On the basis of written representations received from the directors as on March 31, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to the adequacy and the operating effectiveness of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure 2" to this report;
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - iv. Due to restriction and lock down laid by the government due to COVID 19 pandemic, it was impractical for us to attend the physical verification of cash and inventory. Consequently, we have performed related alternative audit procedure and obtained sufficient appropriate audit evidence for existence of inventory and cash as on March 31, 2021.

Our opinion is not modified in respect of the above matter.

For Jain Agarwal and Company.
Chartered Accountants
FRN: 024866N

Sd/-

CA KARAN JAIN
(Partner)
Membership No: 521992

Place: New Delhi
Date: 12th July, 2021

Annexure 1 to the Independent Auditor's report of even date on the Financial Statements of Dr Lalchandani Labs Limited

Annexure to the Auditors' Report

The Annexure referred to in our report to the members of Dr Lalchandani Labs Limited for the year Ended on 31.03.2021. We report that:

S. No.	Particulars	Auditors Remark
(i)	(a) whether the company is maintaining proper records showing full particulars, including quantitative details and situation of fixed assets;	Yes, the company is maintaining the proper records in regards to its Fixed assets & their location.
	b) whether these fixed assets have been physically verified by the management at reasonable intervals; whether any material discrepancies were noticed on such verification and if so, whether the same have been properly dealt with in the books of account;	Yes
	(c) whether the title deeds of immovable properties are held in the name of the company. If not, provide the details thereof;	The company has acquired a property by way of an agreement to sell during the financial year 2017-18. As per the representations from the management, the said property has been mortgaged with Equitas Small Finance Bank during the financial year 2020-21.
(ii)	whether physical verification of inventory has been conducted at reasonable intervals by the management and whether any material discrepancies were noticed and if so, whether they have been properly dealt with in the books of account;	Yes
(iii)	whether the company has granted any loans, secured or unsecured to companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under section 189 of the Companies Act, 2013. If so,	No fresh loans have been granted by the company during the financial year 2020-21.
	(a) whether the terms and conditions of the grant of such loans are not prejudicial to the company's interest;	Yes
	(b) whether the schedule of repayment of principal and payment of interest has been stipulated and whether the repayments or receipts are regular;	Yes
	(c) if the amount is overdue, state the total amount overdue for more than ninety days, and whether reasonable steps have been taken by the company for recovery of the principal and interest;	Not applicable
(iv)	in respect of loans, investments, guarantees, and security whether provisions of section 185 and 186 of the Companies Act, 2013 have been complied with. If not, provide the details thereof.	Yes
(v)	in case, the company has accepted deposits, whether the directives issued by the Reserve Bank of India and the provisions of sections 73 to 76 or any other relevant provisions of the Companies Act, 2013 and the rules framed thereunder, where applicable, have been complied with? If not, the nature of such contraventions be stated; If an order has been passed by Company Law Board or National Company Law Tribunal or Reserve Bank of India or any court or any other tribunal, whether the same has been complied with or not?	Not applicable
(vi)	whether maintenance of cost records has been specified by the	Not applicable

	Central Government under sub-section (1) of section 148 of the Companies Act, 2013 and whether such accounts and records have been so made and maintained.	
(vii)	(a) whether the company is regular in depositing undisputed statutory dues including provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues to the appropriate authorities and if not, the extent of the arrears of outstanding statutory dues as on the last day of the financial year concerned for a period of more than six months from the date they became payable, shall be indicated;	The company has generally been regular in deposit of statutory dues except for delays on few instances in case of deposit of TDS, PF & ESI.
	(b) where dues of income tax or sales tax or service tax or duty of customs or duty of excise or value added tax have not been deposited on account of any dispute, then the amounts involved and the forum where dispute is pending shall be mentioned. (A mere representation to the concerned Department shall not be treated as a dispute).	No such dues
(viii)	whether the company has defaulted in repayment of loans or borrowing to a financial institution, bank, Government or dues to debenture holders? If yes, the period and the amount of default to be reported (in case of defaults to banks, financial institutions, and Government, lender wise details to be provided).	The company has been generally regular in repayment of installments of loans from various financial institutions & banks except for delays of few days on few instances.
(ix)	whether moneys raised by way of initial public offer or further public offer (including debt instruments) and term loans were applied for the purposes for which those are raised. If not, the details together with delays or default and subsequent rectification, if any, as may be applicable, be reported;	Not applicable for this financial year
(x)	whether any fraud by the company or any fraud on the Company by its officers or employees has been noticed or reported during the year; If yes, the nature and the amount involved is to be indicated;	No such instance has been reported
(xi)	whether managerial remuneration has been paid or provided in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act? If not, state the amount involved and steps taken by the company for securing refund of the same;	Yes
(xii)	whether the Nidhi Company has complied with the Net Owned Funds to Deposits in the ratio of 1: 20 to meet out the liability and whether the Nidhi Company is maintaining ten per cent unencumbered term deposits as specified in the Nidhi Rules, 2014 to meet out the liability;	Not applicable
(xiii)	whether all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the Financial Statements etc., as required by the applicable accounting standards;	Yes
(xiv)	whether the company has made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review and if so, as to whether the requirement of section 42 of the Companies Act, 2013 have been complied with and the amount raised have been used for the purposes for which the funds were raised. If not, provide the details in respect of the amount involved and nature of non-compliance;	No such issue has been made during the Financial year 2020-2021.
(xv)	whether the company has entered into any non-cash transactions with directors or persons connected with him and if so, whether the provisions of section 192 of Companies Act, 2013 have been complied with	No such transactions have been entered during the year.

(xvi)	whether the company is required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 and if so, whether the registration has been obtained.	Not applicable
-------	--	----------------

For Jain Agarwal and Company
Chartered Accountants
Firm's registration number: 024866N

Place: New Delhi
Date: 12th July, 2021

Sd/-
CA KARAN JAIN
Partner
Membership number: 521992

"Annexure 2" to the Independent Auditor's Report of even date on the Standalone Financial Statements of Dr Lalchandani Labs Limited

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of Dr Lalchandani Labs Limited ("the Company") as of March 31, 2021 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India". These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance.

Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit

opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on, "the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India."

For Jain Agarwal and Company
Chartered Accountants
FRN: 024866N

Sd/-

CA KARAN JAIN
(Partner)
Membership No: 521992

Place: New Delhi
Date: 12th July, 2021

DR LALCHANDANI LABS LIMITED
Balance Sheet as at 31st March, 2021
CIN:L85320DL2017PLC321605

Particulars	Note No.	As at 31st March, 2021	As at 31st March, 2020
I. Equity and Liabilities			
(1) Shareholders' Funds			
(a) Share Capital	A	43,330,680.00	43,330,680.00
(b) Reserves and Surplus	B	52,189,305.14	42,075,907.39
(2) Non-Current Liabilities			
(a) Long-Term Borrowings	C	26,408,567.78	14,563,939.00
(b) Deferred Tax Liabilities		1,331,864.88	800,748.00
(3) Current Liabilities			
(a) Trade Payables	D	9,615,071.12	11,236,367.87
(b) Other Current Liabilities	E	8,398,932.70	5,252,498.36
(c) Short Term Provision	F	3,129,492.31	1,581,359.00
(d) Short term Borrowings	G	7,552,483.13	500,570.50
Total		151,956,397.06	119,342,070.12
II. Assets			
(1) Non-Current Assets			
(a) Fixed Assets	H		
(i) Tangible Assets		47,300,479.39	33,162,870.64
(ii) Intangible Assets		5,135,388.96	1,548,559.96
(c) Other Non-Current Investments	I	2,410,072.00	2,410,072.00
(d) Other Non-Current Assets	J	2,286,769.60	3,430,154.00
(e) Long term loan and advances	K	9,201,762.00	3,174,512.00
(f) Deferred Tax Assets		-	-
(2) Current Assets			
(a) Inventories	L	6,769,580.00	4,970,270.00
(b) Trade Recieveable	M	39,811,360.41	33,275,117.00
(c) Cash and Cash Equivalents	N	28,923,969.10	22,527,538.14
(d) Other Current assets	O	5,817,015.60	4,225,541.38
(e) Short Term Loans and Advances	P	4,300,000.00	10,617,435.00
Total		151,956,397.06	119,342,070.12

Significant Accounting Policies and Note to Accounts annexed hereto forming part of this balance sheet.

This is the balance sheet referred to in our report of even date.

For Jain Agarwal & Company

Chartered Accountants
FRN 024866N

Sd/-

CA. Karan Jain
Partner
Mem No. 521992

Place : New Delhi
Date : 12.07.2021

For Dr Lalchandani Labs Limited

Sd/-

Dr Arjan Lalchandani
Chairman & Managing Director
DIN - 07014579

Sd/-
Anchal Gupta
CFO
DIN - 07873466

Sd/-

Mohit Lalchandani
Whole Time Director & CEO
DIN-07873508

Sd/-
CS Swati Poddar
Company Secretary
M.No- A58616

DR LALCHANDANI LABS LIMITED
Statement of Profit and Loss for the year ended on 31st March, 2021

Particulars	Note No.	As at 31st March, 2021	As at 31st March, 2020
Income			
Revenue from Operations	Q	97,799,873.53	61,038,719.50
Other Income	R	-	-
Total Revenue		97,799,873.53	61,038,719.50
Expenditure			
Cost of Material Consumed	S	36,059,108.94	11,461,516.80
Employee Benefits Expenses	V	6,810,696.60	8,620,740.47
Finance Costs	W	3,259,604.28	1,849,827.40
Depreciation and Amortisation Expenses	X	5,152,719.40	4,231,067.32
Operations & Other Expenses	Y	32,743,787.25	28,267,919.21
Total Expenses		84,025,916.47	54,431,071.20
Profit Before Tax		13,773,957.06	6,607,648.30
Less: Tax expense			
(1) Current Tax		3,129,492.31	1,581,359.00
(2) Deferred Tax		531,067.00	283,856.00
Profit After Tax		10,113,397.75	4,742,433.30
Earnings per equity share			
(1) Basic		2.33	1.09
(2) Diluted		2.33	1.09

Significant Accounting Policies and Note to Accounts annexed hereto forming part of this Profit & Loss A/c

This is the balance sheet referred to in our report of even date.

For Jain Agarwal & Company
Chartered Accountants
FRN 024866N

For Dr Lalchandani Labs Limited

Sd/-
CA. Karan Jain
Partner
Mem No. 521992

Sd/-
Dr Arjan Lalchandani
Chairman & Managing Director
DIN - 07014579

Sd/-
Mohit Lalchandani
Whole Time Director & CEO
DIN-07873508

Place : New Delhi
Date : 12.07.2021

Sd/-
Anchal Gupta
CFO
DIN - 07873466

Sd/-
CS Swati Poddar
Company Secretary
M.No- A58616

DR LALCHANDANI LABS LIMITED
Cash Flow Statement for the Year Ended 31.03.2021

	<u>Particulars</u>	<u>Amount</u>	<u>Amount</u>
A	<u>Cash Flow From Operating Activities</u>	<u>F.Y.2020-21</u>	<u>F.Y.2019-20</u>
	Net Profit/(Loss) Before Tax	13,773,957	6,607,648
	Adjustment For:		
	Interest Expense	1,793,005	-
	Depreciation	5,152,719	4,231,067
	<u>Operating Profit Before Working Capital Changes</u>	<u>20,719,681</u>	<u>10,838,716</u>
	<u>Changes in Working Capital</u>		
	Change in Sundry Debtors	- 6,536,243	15,001,939
	Change in Other Current Assets	- 448,090	1,280,575
	Change in Trade Payables	- 1,621,297	4,424,662
	Changes in Inventories	- 1,799,310	1,049,630
	Change in Other Current Liabilities	4,694,568	112,633
	Direct Taxes Paid	- 3,129,492	1,576,510
	<u>Net Cash Flows From Operating Activities(A)</u>	<u>11,879,817</u>	<u>971,494</u>
	B <u>Cash Flow From Investing Activities</u>		
	Purchase of Fixed Assets	- 22,877,157	6,139,757
	Receipts from Loans & Advances	-	291,028
	Investments		1,143,385
	Loans and Advances given	290,185	-
	<u>Net Cash Flow From Investing Activities (B)</u>	<u>- 22,586,972</u>	<u>5,287,400</u>
	C <u>Cash Flow From Financing Activities</u>		
	Long Term Borrowings Taken	11,844,629	8,545,938
	Short Term Borrowings Addition	7,051,913	245
	Interest Paid	- 1,793,005	-
	Securities Premium	-	-
	Shares Issued	-	-
	<u>Net Cash Flow From Financing Activities (C)</u>	<u>17,103,537</u>	<u>8,546,183</u>
	<u>Net Change in Cash (A+B+C)</u>	<u>6,396,381</u>	<u>2,287,289</u>
	Cash and Cash Equivalents at the Beginning of Year	<u>22,527,538</u>	<u>20,240,248</u>
	Cash and Cash Equivalents at the End of Year	<u>28,923,969</u>	<u>22,527,538</u>

DR LALCHANDANI LABS LIMITED
Notes forming part of Balance Sheet as at 31st March, 2021

Note "A"
SHARE CAPITAL

Particulars	As at 31st March, 2021		As at 31st March, 2020	
	Number	Amount	Number	Amount
Authorised				
45,00,000 Equity Shares of Rs. 10/- each	4,500,000.00	45,000,000.00	4,500,000.00	45,000,000.00
Issued				
Beginning of the Year 29,33,068 Equity Shares of Rs. 10/-	-	-	-	-
Beginning of the Year 43,33,068 Equity Shares of Rs. 10/-	4,333,068.00	43,330,680.00	4,333,068.00	43,330,680.00
Addition: Through IPO 14,00,000 Equity Shares of Rs. 10/-	-	-	-	-
At the end of the Year 43,33,068 Equity Shares of the Rs.10/-	4,333,068.00	43,330,680.00	4,333,068.00	43,330,680.00
Subscribed and Paid up				
43,33,068 Equity Shares of Rs. 10/- each	4,333,068.00	43,330,680.00	4,333,068.00	43,330,680.00
Total	4,333,068.00	43,330,680.00	4,333,068.00	43,330,680.00

Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting period

Particulars	As at 31st March, 2021		As at 31st March, 2020	
	Number	Amount	Number	Amount
Shares outstanding at the beginning of the year	4,333,068.00	43,330,680.00	4,333,068.00	43,330,680.00
Shares Issued during the year through IPO	-	-	-	-
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	4,333,068.00	43,330,680.00	4,333,068.00	43,330,680.00

Shares in the company held by each shareholder holding more than 5 percent shares

Name of the shareholder	As at 31st March, 2021		As at 31st March, 2020	
	No. of shares held	% of holding	No. of shares held	% of holding
Dr. Arjan Lalchandani	2,386,851.00	55.08	2,386,851.00	55.08
Mr. Amit Charan	220,000.00	5.07	220,000.00	5.07
Total	2,606,851.00	60.15	2,606,851.00	60.15

Sd/-
Arjan Lalchandani
Managing Director
DIN-07015479

Sd/-
Anchal Gupta
CFO
DIN - 07873466

Sd/-
Mohit Lalchandani
Whole Time Director & CEO
DIN-07873508

Sd/-
CS Swati Poddar
Company Secretary
M.No- A58616

DR LALCHANDANI LABS LIMITED
Notes forming part of Balance Sheet as at 31st March, 2021

Particulars	As at 31st March, 2021	As at 31st March, 2020
Note "B"		
RESERVES & SURPLUS		
(a) Securities Premium Account		
Opening Balance	29,223,090.00	29,223,090.00
Add: Amount Received during the year*	-	-
Less: Utilised during the year	-	-
Issue of Bonus shares	-	-
Closing Balance	29,223,090.00	29,223,090.00
(b) Revaluation Reserve		
Opening Balance	150,827.00	150,827.00
Add: Additions during the year	-	-
Less : Utilised during the year	-	-
Closing Balance	150,827.00	150,827.00
(c) Surplus / (Deficit) in Statement of Profit and Loss		
Opening balance	12,701,990.39	7,959,557.09
(+) Net Profit/(Net Loss) For the current year	10,113,397.75	4,742,433.30
Closing balance	22,815,388.14	12,701,990.39
Total	52,189,305.14	42,075,907.39
Note "C"		
LONG-TERM BORROWINGS		
Loans and Advances from related parties		
Secured	-	-
Unsecured	-	4,408,000.00
	-	4,408,000.00
Loans and Advances from other parties		
Secured*	16,218,015.75	9,659,476.00
Unsecured **	16,611,376.03	3,017,978.83
	32,829,391.78	12,677,454.83
Less: Current Maturities	6,420,824.00	2,521,515.83
Total	26,408,567.78	14,563,939.00
* The secured loans availed from Equitas Small Finance Bank are secured by way of charge on the residential property of the promoters situated at New Delhi. This loan is further secured by way of charge on current assets of the company. The secured long term borrowings also includes the vehicle loan availed by the company. These loans are also secured by way of personal guarantees of the promoter directors of the company.		
**The unsecured long term borrowings of the company from other parties includes the various business loans availed from ICICI Bank, Aditya Birla Finance, Tata Capital Finance, IDFC Bank, HDFC Bank etc. These loans are secured by way of personal guarantees of the promoter directors of the company.		
Note "D"		
TRADE PAYABLES		
Due to MSME	4,155,716.20	1,006,891.00
Due to Others	5,459,354.92	10,229,476.87
Total	9,615,071.12	11,236,367.87
Note "E"		
OTHER CURRENT LIABILITIES		
(a) Audit Fees Payable	331,500.00	457,000.00
(b) Salary Payable	249,469.00	551,550.16
(c) Other Payable	1,397,139.70	1,722,432.37
(d) Current Maturities of Long term borrowings	6,420,824.00	2,521,515.83
Total	8,398,932.70	5,252,498.36

DR LALCHANDANI LABS LIMITED
Notes forming part of Balance Sheet as at 31st March, 2021

Particulars	As at 31st March, 2021	As at 31st March, 2020
Note "F"		
SHORT TERM PROVISION		
(a) Provision for Tax	3,129,492.31	1,581,359.00
Total	3,129,492.31	1,581,359.00

Income Tax:

The Company is subject to Indian Income Tax Act, 1961. The Company is assessed for tax on taxable profits determined

Note "G"

SHORT TERM BORROWINGS

(a) Andhra Bank -Overdraft*	-	500,570.50
(b) Equitas Bank -Overdraft*	7,552,483.13	-
Total	7,552,483.13	500,570.50

*The short term borrowings & overdraft limits availed from Equitas Small Finance Bank are secured by way of charge on the residential property of the promoters situated at New Delhi. This loan is further secured by way of charge on current assets of the company. The secured short term borrowings also includes the installments of vehicle loan availed by the company. These loans are also secured by way of personal guarantees of the promoter directors of the company.

Note "I"

OTHER NON-CURRENT INVESTMENTS

Non-Trade Investments - Bullion	2,410,072.00	2,410,072.00
Total	2,410,072.00	2,410,072.00

Note:

Note "J"

OTHER NON-CURRENT ASSETS

(a) Preliminary Expenses*	2,286,769.60	3,430,154.00
(b) Security Deposits	-	-
Total	2,286,769.60	3,430,154.00

*The preliminary expenses includes the expenses incurred by the company for the initial public issue brought out on BSE

Note "K"

LONG TERM LOAN AND ADVANCES

(a) Performance BG-DDA/DJB	60,000.00	60,000.00
(b) Security Deposit on Rent	1,764,600.00	1,455,600.00
(c) Other Security Deposits	1,658,912.00	1,658,912.00
(d) Loans & advances to others	4,878,000.00	-
(e) Loans & advances to related parties	840,250.00	-
Total	9,201,762.00	3,174,512.00

Sd/-

Arjan Lalchandani
Chairman & Managing Director
DIN - 07014579

Sd/-

Mohit Lalchandani
Whole Time Director & CEO
DIN-07873508

Sd/-

Anchal Gupta
CFO
DIN - 07873466

Sd/-

CS Swati Poddar
Company Secretary
M.No- A58616

DR LALCHANDANI LABS LIMITED
Notes forming part of Balance Sheet as at 31st March, 2021

Particulars	As at 31st March, 2021	As at 31st March, 2020
Note "L"		
INVENTORIES		
Stock of Reagents, chemicals, surgicals and laboratory supplies (As taken, valued and certified by management)	6,769,580.00	4,970,270.00
Total	<u><u>6,769,580.00</u></u>	<u><u>4,970,270.00</u></u>

The company's business does not involve any conversion process for materials. Reagents and chemicals are used to conduct various pathology tests and are consumed in the business.

Note "M"

TRADE RECEIVABLES

(a) Due over six months:

Considered good(unsecured)	14,599,559.00	9,106,620.00
Considered doubtful	-	-
	<u>14,599,559.00</u>	<u>9,106,620.00</u>
Less: Provision for doubtful debts	-	-
	<u>14,599,559.00</u>	<u>9,106,620.00</u>

(b) Others:

(a) Due for less than six months:

Considered good(unsecured)	25,211,801.41	24,168,497.00
Considered doubtful	-	-
	<u>25,211,801.41</u>	<u>24,168,497.00</u>
Less: Provision for doubtful debts	-	-
	<u>25,211,801.41</u>	<u>24,168,497.00</u>

Total

39,811,360.41

33,275,117.00

The average credit period from service is 0-60 days. No interest is charged on the trade receivables for the amount overdue above the credit period.

Note "N"

CASH AND CASH EQUIVALENTS

(a) Balance with Banks:

(i) Andhra Bank	10,728.98	1,305.00
(ii) Icici Bank	3,382,478.77	13,031.36
(iii) Yes Bank	1,804.00	1,804.00
(iv) AU Bank	912,199.37	-

(b) Cash in hand

Total

24,616,757.98

22,511,397.18

28,923,969.10

22,527,537.54

Note "O"

OTHER CURRENT ASSETS

TDS receivable	3,374,344.60	3,375,296.10
Prepaid Insurance	187,172.00	25,240.28
Other advances	-	797,174.00
Advance to suppliers	2,227,668.00	-
Deposit with PF Department	27,831.00	27,831.00
Total	<u><u>5,817,015.60</u></u>	<u><u>4,225,541.38</u></u>

DR LALCHANDANI LABS LIMITED
Notes forming part of Balance Sheet as at 31st March, 2021

Particulars	As at 31st March, 2021	As at 31st March, 2020
Note "P"		
SHORT TERM LOANS AND ADVANCES		
Loans & advances to related parties	-	840,250.00
Loans & advances to employees	637,000.00	992,100.00
Loans & advances to others	3,663,000.00	8,785,085.00
Total	<u><u>4,300,000.00</u></u>	<u><u>10,617,435.00</u></u>

Sd/-
Arjan Lalchandani
Chairman & Managing Director
DIN : 07014579

Sd/-
Mohit Lalchandani
Whole Time Director & CEO
DIN-07873508

Sd/-
Anchal Gupta
CFO
DIN - 07873466

Sd/-
CS Swati Poddar
Company Secretary
M.No- A58616

DR LALCHANDANI LABS LIMITED
Notes forming part of Profit & Loss Account as at 31st March, 2021

Particulars	As at 31st March, 2021	As at 31st March, 2020
Note "Q"		
REVENUE		
(a) Sales from Services	97,799,873.53	61,038,719.50
Total	97,799,873.53	61,038,719.50
Note:		
Note "R"		
OTHER INCOME		
(i) Interest on Income Tax Refund	-	-
Total	-	-
Note "S"		
COST OF MATERIAL CONSUMED		
Opening Stock of Consumables	4,970,270.00	3,920,640.00
Add: Purchases During the Year	37,858,418.94	12,511,146.80
Less: Closing Stock	6,769,580.00	4,970,270.00
Total	36,059,108.94	11,461,516.80
Note "V"		
EMPLOYEE BENEFITS EXPENSE		
(a) Salaries and Wages		
(i) Salaries, wages and bonus	3,700,572.00	5,068,202.00
(ii) Director remuneration	2,875,000.00	2,956,128.00
(b) Staff Welfare Expenses	235,124.60	596,410.47
Total	6,810,696.60	8,620,740.47
Note "W"		
FINANCE COSTS		
(a) Interest Expenses	1,793,004.89	1,591,405.86
(b) Bank Charges	1,466,599.39	258,421.54
Total	3,259,604.28	1,849,827.40
Note "X"		
DEPRECIATION & AMORTISATION EXPENSES		
(a) Depreciation of property, plant and equipments	4,718,308.40	3,838,964.28
(b) Amortisation of Intangible assets	434,411.00	392,103.04
Total	5,152,719.40	4,231,067.32
Note "Y"		
OPERATING AND OTHER EXPENSES		
Advertisement Expenses	312,668.96	1,897,279.07
Audit Fees	354,000.00	354,000.00
Business Promotion Expense	9,000.00	54,518.33
Bad debts written off	-	734,840.00
Conveyance	1,395,940.12	1,301,546.09
Consumable Stores	30,180.00	36,268.00
Donation	1,000,000.00	-
Electricity & Water Expenses	1,142,260.76	1,092,035.72
Office Expenses	81,761.00	16,704.00
Insurance Expenses	145,749.28	237,288.44
Professional Expenses	3,816,913.00	1,915,131.00

DR LALCHANDANI LABS LIMITED
Notes forming part of Profit & Loss Account as at 31st March, 2021

Particulars	As at 31st March, 2021	As at 31st March, 2020
Legal Charges	117,947.00	159,434.00
Laboratory Testing Charges	3,063,710.00	3,774,594.00
Rental & Hire charges	7,915,382.81	7,793,253.00
Repair & Maintenance	288,829.00	260,664.20
Telephone and Internet Expenses	348,333.27	377,135.13
Newspaper and Periodicals	-	100,300.00
Printing and Stationery	380,404.00	351,888.00
Contractual Charges	8,915,046.00	5,399,602.55
Interest on TDS	288,419.00	-
Prior Period Expenses	91,943.00	-
Other Expenses	3,045,300.05	2,411,437.68
Total	<u>32,743,787.25</u>	<u>28,267,919.21</u>

Sd/-
Arjan Lalchandani
Chairman & Managing Director
DIN : 07014579

Sd/-
Mohit Lalchandani
Whole Time Director & CEO
DIN-07873508

Sd/-
Anchal Gupta
CFO
DIN - 07873466

Sd/-
CS Swati Poddar
Company Secretary
M.No- A58616

Notes forming part of Balance Sheet as at 31st March 2021

Note "H" : Tangible Assets / Depreciation

Description of Tangible Assets	Gross Block				Depreciation			Net Block	
	As at 01.04.2020	Additions	Deletions	As at 31.03.2021	As at 01.04.2020	For the Year	As at 31.03.2021	As at 31.03.2021	As at 31.03.2020
Tangible Assets									
Centaur Xp	2,017,100	-	-	2,017,100	625,399	248,204	873,603	1,768,896	2,017,100
Xray Polysko-5	247,865	-	-	247,865	76,708	30,500	107,208	217,365	247,865
Cr System (Digital)	419,987	-	-	419,987	130,388	51,680	182,068	368,307	419,987
Mobile Xray	654,332	-	-	654,332	88,549	51,837	140,386	602,495	654,332
Ultrasound Machine Accusen Pe 300	2,703,421	-	-	2,703,421	401,044	232,206	633,250	2,471,215	2,703,421
5 Part Bechman Coulter	120,961	-	-	120,961	59,664	23,817	83,481	97,144	120,961
Autoclave	13,367	-	-	13,367	6,547	2,632	9,179	10,735	13,367
Semi Automated Coagulation Analyzer	188,608	-	-	188,608	33,347	18,847	52,194	169,761	188,608
Computer & Accessories	104,761	-	-	104,761	54,931	34,413	89,344	70,348	104,761
Desktop Computers	169,635	153,880	-	323,515	290,341	59,509	349,850	264,006	169,635
Air Conditioners Split	812,316	232,770	-	1,045,086	198,719	93,184	291,903	951,902	812,316
Air Conditioners(Vrv)									202,536
Genset	202,536	-	-	202,536	50,339	19,935	70,274	182,601	221,963
Civic Car	221,963	-	-	221,963	526,177	146,175	672,352	75,788	51,449
Mobile Phones Executives	51,449	12,990	-	64,439	37,451	13,482	50,933	50,957	722,354
D10	722,354	-	-	722,354	180,348	71,100	251,448	651,254	26,547
Attendance Machine	26,547	-	-	26,547	9,183	7,302	16,485	19,245	59,223
Printer / Bluetooth Printer	59,223	-	-	59,223	24,936	17,752	42,688	41,470	32,966
Barcode Printer	32,966	-	-	32,966	24,884	10,829	35,713	22,137	101,277
UPS	101,277	33,906	-	135,183	41,091	23,792	64,883	111,391	8,480
Heater	8,480	-	-	8,480	3,015	1,193	4,208	7,287	30,687
Tritek 1 Qc	30,687	-	-	30,687	11,037	4,313	15,350	26,374	12,841
Car Battery	12,841	-	-	12,841	3,559	1,580	5,139	11,261	11,155,154
Building & Building Punjabi Bagh	11,155,154	2,396,450	-	13,551,604	1,940,162	852,279	2,792,441	12,699,325	448,858
Renault Car	448,858	-	-	448,858	274,143	88,403	362,546	360,455	6,855,964
Other Plant And Machinery	6,855,964	4,586,733	-	11,442,697	1,345,168	1,009,310	2,354,478	10,433,387	3,829,465
Furniture, Fixture And Electrical Fittings	3,829,465	3,762,450	-	7,591,915	1,591,329	1,093,574	2,684,903	6,498,341	123,836
Centus HA 100 Cell Counter Machine	123,836	-	-	123,836	6,164	8,705	14,869	115,131	1,366,329
Excise 2 System (OUS)	1,366,329	-	-	1,366,329	49,671	96,049	145,720	1,270,280	447,557
Fuji CR System Prime T	447,557	-	-	447,557	27,443	31,462	58,905	416,095	13,031
Invertor	13,031	-	-	13,031	169	2,852	3,021	10,179	-
CFX96 Touch System	-	1,593,000	-	1,593,000	-	59,547	59,547	1,533,453	-
Bio Safety Cabinet	-	295,000	-	295,000	-	14,327	14,327	280,673	-
Cars	-	5,480,236	-	5,480,236	-	279,905	279,905	5,200,331	-
Laptop	-	95,900	-	95,900	-	7,866	7,866	88,034	-
Deep Freezer	-	212,600	-	212,600	-	9,743	9,743	202,857	33,162,868.79
Sub Total	33,162,869	18,855,915	-	52,018,784	8,111,906	4,718,308	12,830,210.53	47,300,479.39	
Intangible Assets									
Website	187	-	-	187	49,750	187	49,937	0	187

Busy	52,325	-	-	52,325	64,707	25,809	90,516	26,516	52,325
Lab Software (Lab Software + Software + Software	1,496,048	4,000,000	-	5,496,048	600,095	406,025	1,006,120	5,090,023	14,96,048
Tally	-	21,240	-	21,240		2,390	2,390	18,850	-
Sub Total	1,548,560	4,021,240	-	5,569,800	714,552	434,411	1,148,963.04	5,135,388.96	15,48,559.96
Total	34,711,429	22,877,155	-	57,588,584	8,826,458	5,152,719	13,979,174	52,435,868	3,47,11,429

DR. LALCHANDANI LABS LIMITED

Provision for Taxation

	<u>2020-21</u>	<u>2019-20</u>
Profit Before Tax	13,773,643.61	6,607,648.30
Add.: Depreciation as per Co. Act	5,152,719.40	4,231,067.00
Add:- Interest on Tds & Income Tax	276,957.00	202,676.00
Add:- Penalty for EPF & ESIC	9,869.00	72,271.00
Add:- Late Payment of Interest	1,593.00	-
Add:- Prior Period Expenses	91,943.00	279,904.36
Add:- Donation (1/2)	500,000.00	-
	<u>19,806,725.01</u>	<u>11,393,566.66</u>
Less.: Dep. as per I.Tax Act	7,364,816.88	5,311,416.00
Total income	<u>12,441,908.13</u>	<u>6,082,150.66</u>
Rounded Off	12,434,410.00	6,082,150.00
Net Taxable Income	12,434,410.00	6,082,150.00
Gross Provision For Income Tax	3,129,492.31	1,581,359.00
MAT Credit	-	-
Net Provision For Income Tax	NIL	NIL
Advance Tax	-	-
TDS	-	-
Tax Payable / Refundable	<u>3,129,492</u>	<u>1,581,359.00</u>

Calculation of Deferred Tax Liability

	<u>2020-21</u>	<u>2019-20</u>
Balance as per Income Tax	47,143,970.37	31,631,632.00
Balance as per Companies Act	52,435,868.35	34,711,430.00
<u>Difference</u>	<u>- 5,291,897.98</u>	<u>- 3,079,798.00</u>
Deferred Tax Liability till date as on 31-03-2021	- 1,331,864.88	- 800,747.48
Deferred Tax Liability till date as on 31-03-2020	800,747.00	516,892.00
Creation of DTL required during F Y 2020-21	531,067.00	283,855.00

Notes to accounts forming part of the Balance Sheet as at 31st March, 2021 and Statement of Profit and Loss for the year ended on that date.

Notes on Accounts

GENERAL INFORMATION

Dr. Lalchandani Labs Limited (“the Company”) is a public company domiciled in India and incorporated on August 02, 2017 under the provisions of the Companies Act, 2013. The Company is engaged in the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immunology, virology, cytology, and other pathological and radiological investigations.

The Company was incorporated as a Public Limited Company with effect from August 02, 2017 and consequently the Company has taken over the running business of Dr A Lalchandani Pathology Laboratories (Partnership firm) on going concern basis with effect from August 31, 2017. The equity shares of the Company are listed on the Bombay Stock Exchange.

The registered address and principal place of business of the Company is M-20, Basement, Greater Kailash -I, New Delhi- 110048.

SIGNIFICANT ACCOUNTING POLICIES

2.1 Statement of compliance

In accordance with the notifications issued by the Ministry of Corporate Affairs, the aforesaid financial statements comply with the Accounting Standards specified under section 133 of the Companies Act, 2013 & read with Rule 7 of the Companies (Accounts) Rules, 2014 and the Companies (Accounting Standards) Amendment Rules, 2016.

2.2 Basis of preparation and presentation

These financial statements have been prepared on the accrual and going concern basis, and the historical cost convention except for certain financial instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies below.

Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.

Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date under current market conditions.

2.3 Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable. Revenue is reduced for trade allowances for deduction, rebates and other similar allowances. Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognized:

2.3.1 Laboratory income

Medical testing charges consists of fees received for various tests conducted in the field of pathology and radiology and are recognized on accrual basis when the samples are registered for the purpose of conducting the tests, net of discounts, if any.

2.3.2 Interest

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

2.4 Leasing

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee. All other leases are classified as operating leases.

Rental income from operating leases is recognised on a straight-line basis over the term of the relevant lease. Where the rentals are structured solely to increase in line with expected general inflation to compensate for the Company's expected inflationary cost increases, such increases are recognised in the period in which such benefits accrue.

2.4.1 The Company as lessee

Rental expense from operating leases is generally recognised on a straight-line basis over the term of the relevant lease. Contingent rentals, if any, arising under operating leases are recognised as an expense in the period in which they are incurred.

2.5 Functional and presentation currency

Items included in the financial statements are measured using the currency of the primary economic environment in which the entity operates ('the functional currency'). The financial statements are presented in Indian rupee (INR), which is the Company's functional and presentation currency.

2.6 Employee benefits

Employee benefits include provident fund, gratuity, ESIC, Group Health Insurance, Accidental Insurance for runners and compensated absences.

2.6.1 Defined contribution plan

Employee benefit under defined contribution plan comprising of provident fund is recognised based on the amount of obligation of the Company to contribute to the plan. The provident fund contribution is paid to provident fund authorities. The amounts are expensed during the year.

2.6.2 Defined benefit plan

The Company's gratuity plan is a defined benefit plan. The present value of the obligation under such defined benefit plan is determined based on actuarial valuation using the projected unit credit method, which recognizes each period of service as giving rise to additional unit of employee benefit entitlement and measures each unit separately to build up the final obligation. The obligation is measured at the present value of the estimated future cash flows. The discount rate used for determining the present value of the obligation under defined benefit plans, is based on the prevailing market yields on government securities as at the balance sheet date.

Re-measurement, comprising actuarial gains and losses, the effect of the changes to the asset ceiling (if applicable) and the return on plan assets (excluding net interest), is reflected immediately in the balance sheet with a charge or credit recognised in other comprehensive income in the period in which they occur. Re-measurement recognised in other comprehensive income is reflected immediately in retained earnings and is not reclassified to profit or loss. Past service cost is recognised in

Statement of profit and loss in the period of a plan amendment. Net interest is calculated by applying the discount rate at the beginning of the period to the net defined benefit liability or asset. The company was incorporated in August 2017 and had recruited the employees with effect from September 01, 2017. The company has not provided for any provision for gratuity in their books of accounts for the financial year ended March 31, 2021.

Defined benefit costs are categorized as follows:

- Service cost (including current service cost, past service cost, as well as gains and losses on curtailments and
- Net interest expense or income; and
- Re-measurement

The Company presents the first two components of defined benefit costs in profit or loss in the line item 'Employee benefits expense'. Curtailment gains and losses are accounted for as past service costs.

The Company intends to take the various policies with insurer managed funds to meet its obligation towards gratuity. Liability with respect to the gratuity plan is determined based on an actuarial valuation done by an independent actuary.

The gratuity benefit obligation recognised in the standalone Balance Sheet represents the actual deficit or surplus in the Company's defined benefit plans. Any surplus resulting from this calculation is limited to the present value of any economic benefits available in the form of refunds from the plans or reductions in future contributions to the plans.

A liability for a termination benefit is recognised at the earlier of when the entity can no longer withdraw the offer of the termination benefit and when the entity recognizes any related restructuring costs.

Short-term employee benefits

The undiscounted amount of short-term employee benefits expected to be paid in exchange for the services rendered by employees are recognised during the year when the employees render the service. These benefits include performance incentive and compensated absences which are expected to occur within twelve months from the end of the period in which the employee renders the related service.

The cost of short-term compensated absences is accounted as under:

- a) In case of accumulated compensated absences, when employees render the services that increase their entitlement of future compensated absences; and
- b) In case of non-accumulating compensated absences, when the absences occur.

Long-term employee benefits

Compensated absences which are not expected to occur within twelve months from the end of the period in which the employee renders the related service are recognised as a liability at the present value of the obligation as at the Balance Sheet date.

2.7 Income tax expense represents the sum of the tax currently payable and deferred tax.

2.7.1 Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from 'profit before tax' as reported in the Statement of profit and loss because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

2.7.2 Deferred tax

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities are not recognised if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax assets include Minimum Alternate Tax ('MAT') paid in accordance with the tax laws in India, which is likely to give future economic benefits in the form of availability of set off against future income tax liability. Accordingly, MAT is recognised as deferred tax asset in the Balance Sheet when the asset can be measured reliably and it is probable that the future economic benefit associated with asset will be realized.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current and deferred tax for the year

Current and deferred tax are recognised in profit or loss, except when they relate to items that are recognized in other comprehensive income or directly in equity, in which case, the current and deferred tax are also recognised in other comprehensive income or directly in equity respectively.

2.8 Property, plant and equipment

Property, plant and equipment are stated at cost of acquisition or construction less accumulated depreciation less accumulated impairment, if any.

The cost of Property, plant and equipment (PPE) comprises its purchase price net of any trade discounts and rebates, any import duties and other taxes (other than those subsequently recoverable from the tax authorities), any directly attributable expenditure on making the asset ready for its intended use, other incidental expenses, present value of decommissioning costs (where there is a legal or constructive obligation to decommission) and interest on borrowings attributable to acquisition of qualifying fixed assets up to the date the asset is ready for its intended use.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with

the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. The other repairs and maintenance of revenue nature are charged to profit or loss during the reporting period in which they are incurred.

Property, plant and equipment are tested for impairment whenever events or changes in circumstances indicate that an asset may be impaired. If an impairment loss is determined, the remaining useful life of the asset is also subject to adjustment. If the reasons for previously recognised impairment losses no longer exists, such impairment losses are reversed and recognised in income. Such reversal shall not cause the carrying amount to exceed the amount that would have resulted had no impairment taken place during the preceding periods.

Depreciation methods, estimated useful lives and residual value

Depreciation on all assets is provided using the Written Down Value (WDV) Method at the rates computed based on the useful lives of the assets estimated by the management on a pro-rata basis from the month in which each asset is put to use to allocate their cost, net of their residual values, over their estimated useful lives.

Estimated useful life of assets are as follows which is based on technical evaluation of the useful lives of the assets:

S.No	Asset Description	Estimated Life of Asset (in years)
1.	Building	15
2.	Plant and Equipment	8-13
3.	Computers	3
4.	Office Equipment	5
5.	Vehicles	8-10
6.	Furniture and Fixtures	8-10
7.	Intangible Assets	3-5

The assets' residual values, estimated useful lives and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

All assets, the individual written down value of which at the beginning of the year is Rs. 5,000 or less, are depreciated at the rate of 100%. Assets purchased during the year costing Rs. 5,000 or less are depreciated at the rate of 100%.

Gains and losses on disposal are determined by comparing proceeds with carrying amount and are credited / debited to profit or loss.

2.9 Intangible assets

2.9.1. Intangible assets acquired separately

Trademarks and software are carried at cost which is incurred and stated in the relevant license agreement with the technical know-how provider less accumulated amortization and accumulated impairment losses. Amortization is recognised on a straight line basis over their estimated useful lives. The estimated useful lives and amortization method are reviewed at end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.

2.9.2 Amortization methods and useful lives

Trademarks and software are amortized on a straight line basis over its estimated useful life i.e. 5 years. An intangible asset is derecognized when no future economic benefits are expected from use.

2.10 Inventories

Inventories comprise of reagents, chemicals, surgical and laboratory supplies and stores and others and are valued at lower of cost and net realizable value. Cost is determined on moving weighted average basis.

2.11 Provisions, contingent liability and contingent asset

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

Contingent assets are disclosed in the financial statements by way of notes to accounts when an inflow of economic benefits is probable.

Contingent liabilities are disclosed in the financial statements by way of notes to accounts, unless possibility of an outflow of resources embodying economic benefit is remote.

2.12 Financial instruments

Financial assets and financial liabilities are recognised when Company becomes a party to the contractual provisions of the instruments.

Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognised immediately in the Statement of Profit and Loss.

2.12.1. Cash and cash equivalents

The Company considers all highly liquid financial instruments, which are readily convertible into known amounts of cash that are subject to an insignificant risk of change in value and having original maturities of three months or less from the date of purchase, to be cash equivalents. Cash and cash equivalents consist of balances with banks which are unrestricted for withdrawal and usage.

2.13 Earnings per share

Basic earnings per share are computed by dividing the profit after tax by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the profit after tax as adjusted for dividend, interest and other charges to expense or income (net of any attributable taxes) relating to the dilutive potential equity shares by the weighted average number of equity shares considered for deriving basic earnings per share and

also the weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares.

2.14 Operating cycle

The Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

2.15 Cash Flow Statement

Cash flows are reported using the indirect method, whereby profit for the year is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows are segregated into operating, investing and financing activities.

2.16 Dividends

The company has not declared any dividend for the financial year 2020-2021.

2.17 Use of estimates and judgements

The preparation of financial statements in conformity with AS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amount of assets, liabilities, income, expenses and disclosures of contingent assets and liabilities at the date of these financial statements and the reported amount of revenues and expenses for the years presented. Actual results may differ from the estimates.

Estimates and underlying assumptions are reviewed at each balance sheet date. Revisions to accounting estimates are recognised in the period in which the estimates are revised and future periods affected.

2.18 Loans availed

During the financial year 2019-20, the company has availed a secured loan of Rs. 1,00,00,000/- from AU Small Finance Bank Limited which is secured by way of mortgage of property at Lajpat Nagar, New Delhi in the name of the company & other property in the name of the Managing director i.e. Dr Arjan Lalchandani. The said loan has been availed for business expansion purposes.

2.19 Related Party Disclosures

I. Names of related parties and related party relationship

Dr. Arjan Lalchandani (Managing Director of the Company)

Mr. Mohit Lalchandani (Whole-time Director and CEO of the Company)

Mrs. Anchal Gupta (Executive Director/ CFO of the Company)

a. Entities in which key managerial personnel can exercise significant influence

1 CPC Blood Bank

b. Key Managerial Personnel

1 Dr Arjan Lalchandani - Chairman and Managing Director

2 Mr. Mohit Lalchandani - Whole time Director / CEO

3 Mrs. Anchal Gupta- Executive Director / CFO

4 Ms. Swati Poddar – Company Secretary & Compliance Officer

c. Relatives of Key Managerial Personnel

Ms. Manica Gupta – Non Executive Director (Sister of Anchal Gupta)

Information on related party transactions as required by Accounting Standard (AS)-18 for the year ended 31st March, 2021

S.No.	Particulars	Associated Enterprises where Influence / control exist (Rs.)		Relatives to Director/MD/Key persons (Rs.)		Key Managerial Persons(Rs.)	
		Previous Year	Current Year	Previous Year	Current Year	Previous Year	Current Year
1	Managerial Remuneration	NIL	NIL	NIL	NIL	29,56,128	28,75,000
2	Expenses Reimbursements	NIL	NIL	NIL	NIL	6,00,000	5,90,000
3	Sale of Goods	NIL	NIL	NIL	NIL	NIL	NIL
4	Purchase of Goods	NIL	NIL	NIL	NIL	NIL	NIL
5	Commission to Non-Executive Director	NIL	NIL	NIL	NIL	NIL	NIL
6	Sitting Fees Paid to Non-Executive Director	NIL	NIL	NIL	NIL	2,21,000	NIL
7	Other Services	NIL	NIL	NIL	NIL	NIL	NIL
8	Donation	NIL	NIL	NIL	NIL	NIL	NIL
9	Purchase of Assets	NIL	NIL	NIL	NIL	NIL	NIL
10	Amount Receivables	NIL	NIL	NIL	NIL	NIL	NIL
11	Amount Payable	NIL	NIL	NIL	NIL	1,99,622	NIL

For Jain Agarwal & Company
Chartered Accountants
FRN: 024866N

For and on behalf of DR LALCHANDANI LABS LIMITED

Sd/-

CA Karan Jain
Partner
Membership No. 521992

Sd/-

Arjan Lalchandani
Chairman & Managing Director
DIN: 07014579

Place: New Delhi
Date: 06th September, 2021

DR LALCHANDANI LABSLIMITED
CIN-L85320DL2017PLC321605
Regd. Off.: M-20, 20 BASEMENT, GREATER KAILASH-1, NEW DELHI
Email: info@lalchandaniopathlab.com, Website: www.lalchandaniopathlab.com

ATTENDANCE SLIP

(To be presented at the entrance)
ANNUAL GENERAL MEETING ON WEDNESDAY, 29TH SEPTEMBER, 2021 AT 3.00 P.M.
AT GOLDEN PALMS HOTEL, 6 C, OPPOSITE POLICE HEADQUARTER, PATPARGANJ, NEW DELHI-110092
Email: info@lalchandaniopathlab.com

Folio No. _____ DP ID No. _____ ClientID No. _____

Name of the Member Signature _____

Name of the Proxy holder Signature _____

1. Only Member/Proxy holder can attend the Meeting.
2. Member/Proxy holder should bring his/her copy of the Annual Report for reference at the Meeting.

DR LALCHANDANI LABSLIMITED
CIN-L85320DL2017PLC321605
Regd.Off.: M-20 Basement, Greater Kailash-1, New Delhi -110048
Email:info@lalchandaniplab.com,Website:www.lalchandaniplab.com

PROXY FORM

(Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014- Form No.MGT-11)

**Affix
Re. 1/-
Revenue
Stamp**

Name of the Member(s):
Registered address:
E-mail Id:
Folio No. /Client ID No. :
DP ID No

I/We, being the holder(s) ofShares of Dr Lalchandani Labs Limited, hereby appoint:

1. Name:
E-mail Id:
Address:
Signature:_____ ; or failing him
2. Name:
E-mail Id:
Address:
Signature:_____ ; or failing him
3. Name:
E-mail Id:
Address:
Signature:_____

As my/our proxy to attend and vote (on a poll) form/us and on my/our behalf at the Annual General Meeting of the company to be held on_____,_____, 2021 at_____P.M. at_____and at any adjournment thereof in respect of such resolutions as are indicated overleaf:

For Vote-See Note No-3

Resolution No.	Resolutions	Nature of Business	For	Against
1	To consider and adopt the audited standalone financial statements of the Company for the Financial Year ended March 31, 2021, together with the Reports of the Board of Directors and the Auditors thereon.	Ordinary		
2	To approve, with or without modification, re-appoint a director Mrs. Anchal Gupta (DIN: 07873466) who retires by rotation at this annual general meeting and being eligible offers herself for re-appointment.	Ordinary		

Signed this.....day of.....2021

Signature of shareholder
holder(s)

Signature of Proxy

NOTES:

1. This Form in order to be effective should be duly completed and deposited at the Registered Office of the Company at M-20 Basement, Greater Kailash Part-1, New Delhi-110048, not less than 48 hours before the commencement of the Meeting.
2. Those Members who have multiple folios with different joint holders may use copies of this Attendance slip/Proxy.
3. It is optional to put a “X” in the appropriate column against the Resolution indicated in the Box. If you leave the ‘For’ or ‘Against’ column blank against the Resolutions, your Proxy will be entitled to vote in the manner as He/ She thinks appropriate.

NOTES

DR LALCHANDANI LABS LIMITED

CIN - L85320DL2017PLC321605

Regd. Off.: M-20 Basement, Greater Kailash-1, New Delhi-110048

Email: info@lalchandanipathlab.com, Website: www.lalchandanipathlab.com

Tel: 011-4905705